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ABSTRACT 
Background: Respiratory Syncytial Virus (RSV) is a common cause of upper and lower 
respiratory tract infections (LRTI), primarily in children having severe disease manifestation. 
In South Africa, RSV is identified in approximately 25-30% of children hospitalized for 
LRTI. There is a spectrum of RSV-associated LRTI severity.  Understanding associations 
between immune mediators and RSV-LRTI severity could assist clinicians in the triaging for 
level of care. Several cytokines have been implicated in RSV-LRTI severity. 
Aim: Study the associations between cytokine levels from plasma and nasopharyngeal 
aspirate with RSV infection or RSV-associated LRTI severity in hospitalized infants ranging 
from 0-12 months of age. The correlation between plasma and nasopharyngeal aspirate 
cytokine concentrations was also evaluated. 
Methods: Paired plasma and nasopharyngeal aspirate (NPA) samples were collected from 
polymerase chain reaction confirmed RSV-infected infants without coinfection with other 
pathogens that we investigated for. Paired samples were also collected from RSV negative-
control infants (n=31) who did not have any respiratory symptoms. Control-infants were 
scheduled for elective surgery; samples were collected before administration of medication 
and surgical procedure. RSV associated LRTI episodes were grouped into mild (n=89) and 
severe RSV-LRTI (n=113) using the Respiratory Index of Severity in Children (RISC) Score. 
Interferon gamma (IFN-γ), interleukins (IL) IL-1α, IL-1β, IL-4, IL5, IL-6, IL-8, IL-9, IL-10, 
IL-12(p70)IL-13, macrophage inducing protein (MIP-1α), monocyte chemo attractant protein 
(MCP-1), tumour necrosis alpha (TNF-α), Regulated on activation, normal T cell expressed 
and secreted (RANTES) and were measured with multiplex immunosorbent assay using 
Luminex® technology. Cytokine profiles were evaluated for association of RSV-LRTI 
severity and between RSV LRTI cases and controls. 
Results: Comparing hospitalized RSV-associated LRTI to control infants, RSV cases had 
elevated plasma TNF-α (0.7pg/ml vs. 0.5pg/ml; p=0.007), and IL-10 (1.0pg/ml vs. 0.6pg/ml; 
p=0.02) concentrations, and reduced plasma MIP-1α (12pg/ml vs. 28pg/ml; p=0.008) and 
IFN-γ (3pg/ml vs. 5pg/ml; p=0.02) levels. Nasopharyngeal aspirate TNF-α (8.0pg/ml vs. 
1.0pg/ml; p=0.01), IL-8 (2682pg/ml vs. 184pg/ml; p=0.002), MCP-1 (287pg/ml vs. 66pg/ml; 
p<0.001), MIP-1α (27pg/ml vs. 6.7pg/ml; p=0.004) concentrations were elevated in RSV-
LRTI cases compared to control infants. Infants hospitalized with severe RSV-associated 
LRTI (RISC score ≥2) were younger than mild cases (3.9 vs. 4.5 months; p=0.01). In RSV 
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cases, severe RSV-LRTI was associated with increased plasma IFN-γ levels (4pg/ml vs. 
3pg/ml) and NPA MIP-1α concentrations (88pg/ml vs. 50pg/ml, mean; all other values 
medians) compared to mild RSV-LRTI. In a multivariate analysis, NPA MIP-1α levels 
remained associated with RSV-LRTI (p=0.05), but could not predict RSV-LRTI severity. 
Conclusion: This study observed that during RSV-associated LRTI, immune response was 
directed at the respiratory tract. Reduced concentrations of plasma IFN-γ and elevated levels 
of cytokines in the NPA may suggest that the blood of RSV-LRTI cases had reduced number 
of IFN-γ producing cells. There was no evidence of distinct Th1 or Th2 type immune 
response and the cytokines associated with RSV-LRTI severity could not predict the outcome 
of severe RSV-associated LRTI. 
Key words: Respiratory Syncytial Virus, Lower respiratory tract infections, Severity, 
Plasma, Nasopharyngeal aspirate, IFN-γ, MIP-1α, Luminex® 
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Chapter 1: Literature Review 
Respiratory Syncytial Virus (RSV) was initially identified in 1956 from a chimpanzee that 
had an upper respiratory tract infection; and named Chimpanzee Coryza Agent (1, 2). One 
year later, a similar virus now named RSV was isolated from infants with lower respiratory 
tract infection (LRTI) (3). The molecular characteristics of RSV were not elucidated for over 
two decades due to difficulty in culturing the virus (3), and finally published in 1981 (1). 
There is currently no licensed vaccine for RSV and medical interventions are largely 
supportive with no specific treatment against RSV (4). A prophylactic strategy is monoclonal 
antibody, palivizumab (Synagis®, MedImmune), which is recommended in infants with 
underlying risk of severe RSV disease and reportedly has 39-78% efficacy against RSV-
associated hospitalization (5, 6).  
 Taxonomy of RSV  1.1.
Human RSV belongs to the Mononegavirales order (7, 8) and is a member of the 
Paramyxoviridae family made of three genuses: Morbilivirus (example: measles virus), 
Paramyxovirus (examples: human parainfluenza virus types 1 to 4) and the Pneumovirinae 
genus (9, 10). RSV is classified into two subtypes RSV-A and RSV-B, based on genetic and 
antigenic variations of the surface G-protein (11-14). It is an enveloped virus with a single-
stranded negative-sense ribonucleic acid (RNA) genome. The viral envelope includes two 
glycoproteins, the fusion protein (F-protein) and the glycoprotein (G-protein), which play key 
roles in disease pathogenesis (15). The G and F proteins are the most antigenic segments of 
the virus. These proteins are exposed on the surface of the RSV virions and induce 
neutralizing antibodies, therefore have been targeted in vaccine development (16). 
To date 11 different RSV-A and 17 RSV-B genotypes have been identified globally (17).  
RSV-A includes SAA1 (South Africa, A1) (18), NA1, NA2,  GA1 to GA7 (19)  and ON1 
genotypes (14, 17); and RSV-B includes GB1 to GB4, SAB1to SAB3 and BA1 to BA10 
genotypes (17).  
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 Structure of the Respiratory Syncytial Virus  1.2.
The RSV virion is approximately 100-350 nm in diameter. The core of the virion consists of 
nucleocapsid proteins and an encapsulated genome with a lipid bilayer originated from the 
host cell membrane (1). The lipid bilayer from the host also contains viral encoded envelope 
glycoproteins of 11-20 nm in length (Figure 1.1) (20). 
The RSV reference genome has 15 222 nucleotide (RSV A strain A2, GenBank accession 
number M74568) (1, 21). The genome is non-segmented, and is composed of an extended 3’ 
leader region and 5’ trailer regions (9), with 10 genes. The genome encode 11 proteins (15) 
categorised as: non-structural proteins, nucleocapsid-associated proteins, envelope 
glycoproteins, and regulatory proteins (Figure 1.1) (7).  
 
Figure 1.1. The structure of the RSV virion and encoded genome  
From Lambert et.al (2013) (11). 
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 RSV virulence factors 1.3.
The RSV genome and proteins interact with host cell factors. Characterization of these 
interactions holds a key to the development of antiviral treatment and therapeutic intervention 
strategies. 
1.3.1. Leader and trailer regions of RSV genome 
According to Mink et al. (1991), the leader and trailer regions of the RSV genome include 
signals that are important in initiating viral RNA synthesis (9). The leader region is 
approximately 44 nucleotides long with two major functions: i) confers RNA replication 
signals to produce a full replicative antisense that directs the synthesis of the progeny 
genome, and ii) provides transcription signals that result in sub-genomic messenger RNA 
(mRNA) (22).  
The trailer region of the RSV genome is approximately 155 nucleotides long. Studies by 
Hanley et al. (2010) have suggested that the trailer region enhanced the promoter signal 
activity involved in RSV replication. This allows the virus to replicate more rapidly and 
establish itself early in infection before the adaptive immune response has matured. As a 
result, RSV replicates rapidly in order to infect other hosts or host cells (22). Furthermore, the 
trailer region enables RSV to interact with and destabilize the host stress granule (SG) 
response. During environmental stress such as an infection, the SG response is an attempt by 
the host cells to inhibit viral RNA translation by forming stalling RNA-protein complexes in 
the cytoplasm known as stress granules. These complexes form a crucial link for host 
degradation machineries to recognise the viral RNA “tagged” for destruction (23, 24).  
The ability of RSV to interact with the SG response can alter host cytokine response. During 
an infection, the interaction between the virus and host toll-like receptors (TLR) leads to the 
translation of large quantities of cytokines. The inhibition of SG response by the trailer region 
has the potential to augment the expression of pro-inflammatory cytokines, and this can lead 
to tissue damage by the immune response. It is therefore vital that the translation of cytokine 
mRNA is reduced to baseline once the healthy state has been achieved (24).  
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1.3.2. Non-structural proteins 
The RSV non-structural (NS) proteins include NS1 and NS2 proteins. These proteins are 
encoded at the vicinity of the 3’ leader region to ensure that they are highly expressed (7). 
Animal RSV challenge studies with RSV strains engineered to lack the function of non-
structural proteins, demonstrated reduction in lung pathology (25). The NS1 and NS2  
proteins antagonise the  antiviral activity of interferon signals by up regulating the expression 
of suppressor of cytokines signalling (SOCS), a feedback loop which attenuates cytokine 
response (25).  
1.3.3. Nucleocapsid-associated proteins 
The RSV nucleocapsid is composed of nucleoprotein (N protein), polymerase (L protein), 
phosphoprotein (P protein) and matrix proteins (M2-1 and M2-2 proteins) that closely 
associate together (26). These proteins assemble to facilitate the transcription and replication 
of genomic RNA and mRNA (27, 28). The N protein associates with the negative sense 
genomic RNA and the antigenome (29). This interaction shields the genomic material from 
host intracellular recognition by the TLR and other innate immune system pro-inflammatory 
factors that would initiate antiviral responses (7), and also serves as a  transcription start 
signal for the virus L protein. Furthermore, the N protein confers ribonuclease resistance to 
the genome and antigenome (26). 
The L protein functions as the RNA dependent polymerase (28, 30). It replicates the negative 
sense genomic and anti-genomic RNA, and transcribes mRNA. It is also believed that the L 
protein has the ability to cap the 5’ end of the mRNA and methylate the cap. Ribavirin, a 
ribonucleoside analogue, has been used to inhibit the functions of L protein, however has 
clinical limitations to treat RSV infection because of its toxicity (28).  
The P protein provides stability to the nucleocapsid-associated proteins assembly complex 
during RNA synthesis (31). It also acts as L protein cofactor by directing the polymerase to 
the genomic RNA. The interaction of M proteins with the nucleocapsid-associated proteins is 
bridged by M2-1 protein (27). This protein mediates the assembly of new virions and their 
subsequent budding from the host plasma membrane (26). On the other hand, M2-1 protein 
has been reported to prevent early transcription termination (32). Recent in vitro and mice 
model studies by Bailly et al. (2016) inhibited the functions of M2-1 protein with the 
Smoothened Receptor (SMO) and demonstrated a reduction in viral transcription and virus 
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replication (32). SMO is a human protein that forms part of the signal transduction and 
belongs to G-Protein coupled receptors (33). 
1.3.4. Envelope-associated proteins 
The viral envelope consists of glycoproteins, small hydrophobic protein (SH), fusion protein 
(F-protein) and glycoprotein (G-protein), the latter two mediate infection of host cell (15). 
The SH is a transmembrane protein (34) and studies have shown that it can attenuate host cell 
apoptosis by inhibiting host cells from secreting tumour necrosis factor (TNF-α) and using 
alternative pathways, which still need to be explored (34, 35).  
During RSV infection, the F-protein mediates the fusion of the RSV envelop with the host 
cell membrane (36). Furthermore, it facilitates membrane fusion of nearby RSV infected 
respiratory tissue cells to form a “giant cell” known as syncytia (37), and induces the 
expression of IL-1β by macrophages (38). F-protein interacts with immune cells such as 
neutrophils expressing toll-like receptor 4 (TLR4) (39).  F-protein inhibits TLR4 signalling 
during cell entry. (38), This prevents neutrophils to form NETs (Neutrophil Extracellular 
Traps) in a process called NETosis (release of neutrophil extracellular traps, which has 
antimicrobial activity) (39). 
Variations in the G-protein differentiate the RSV group A from B (13, 40). G-protein further 
facilitates the virus to escape the immune responses (13); rendering the host susceptible to 
reinfection by different RSV strains in a life-time (13). The secretion of early warning 
cytokines and other pro-inflammatory mediators is also antagonised by the G-protein (41). 
Both F and G proteins work hand-in-hand to escape the host immune response. The heavily 
glycosylated G and F proteins are the most antigenic segments of the RSV and have been 
targeted in vaccine development as they induce neutralizing antibodies production (16).  
1.3.5. Regulatory proteins 
The viral M2-2 protein acts as the genomic negative sense RNA regulatory factor (42). In 
vitro studies demonstrated that the deletion of this protein was associated with reduced 
accumulation of RSV genomic and complementary genomic RNA which are important in 
RSV replication. The same study observed an increase in the accumulation of transcription 
products showing that M2-2 protein regulates RNA transcription and viral replication (43). It 
assures that sufficient infectious progeny viruses are produced by increasing replication. 
19 
 
 Epidemiology of RSV disease 1.4.
In 2015, pneumonia accounted for an estimated 15.5 % of under 5 years of age childhood 
mortality globally (Figure 1.2)(44). RSV is a common virus, causing upper and LRTI mainly 
in children below one year of age and the elderly (13, 45, 46). Approximately 80% of 
children worldwide are infected with RSV in their first year of life, of which an estimated 
one-third  develop LRTI (11). According to Nair et al. (2010) globally RSV causes 30 
million new LTRI episodes in children under the age of 5 years each year, resulting in 3.4 
million hospitalizations associated with severe disease (47). It is estimated that 90% of the 
deaths due to RSV infection occur in low-middle income countries largely in Africa, South-
East Asia, and Eastern Mediterranean regions (48). In line with these estimates, a study 
conducted in four South African provinces from 2009 to 2012 among children <5 years of 
age reported detection of RSV in 26% of LRTI hospitalized cases using real-time quantitative 
reverse transcription polymerase chain reaction (PCR) (49). 
 
Figure 1.2. Global causes of under 5 years of age mortality 
 From Liu et al. (2016) (44). 
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 Risk factors associated with RSV disease 1.5.
Recognised risk factors for severe RSV-associated LRTI are low-socio economic conditions, 
prematurity, male gender, pre-existing chronic medical conditions, and young age (11, 50, 
51). Nonetheless a substantial proportion of hospital admissions due to RSV are observed in 
previously healthy children with no other underlying risk factors other than young age (52, 
53). In South Africa the incidence of RSV-associated LRTI is increased in Human 
Immunodeficiency Virus-1 (HIV-1) infected and HIV-exposed uninfected (HEU) infants 
(54). RSV-associated LRTI hospitalizations in Gauteng province are mostly limited to the 
pre-winter period, February-March (55). In KwaZulu-Natal RSV hospitalization is commonly 
between December-January and the Western Cape is limited to March (5). 
 RSV exposure and infection 1.6.
RSV is highly contagious, and spreads through droplets containing the virus. The virus can 
also survive on surfaces such as hands and clothing, so it can easily spread through direct 
contact with contaminated surfaces and self-inoculation (56, 57). During a primary infection 
in the nose, the virus makes contact with nucleolin receptors on the apical surface of 
epithelial host cells (58) and enters the cells with aid of the F-protein (59, 60). In the 
nasopharyngeal epithelial cells, RSV incubates for two to eight days, replicates and may 
spread to the bronchioles (12, 56) after which more severe symptoms begin.  
 Clinical manifestation of RSV infection 1.7.
RSV infection manifests with a variety of symptoms that are similar to other respiratory 
infections. One to three days following RSV infection, symptoms such as coughing, sneezing 
and wheezing may manifest, other respiratory symptoms may appear during the incubation 
period of the virus (61). Most upper respiratory tract infections (URTI) caused by RSV are 
characterised by inflammation of the mucosal membrane in the nose (13). Elderly 
individuals, premature infants, and children who are immune compromised or have chronic 
lung or congenital heart disease are at a greater risk of developing severe LRTI symptoms 
following exposure to the virus. RSV infecting the lower respiratory tract can result in 
pneumonia or bronchiolitis and approximately 25% to 40% of infants with primary RSV 
infection will show symptoms of pneumonia or bronchiolitis (62). RSV-associated 
pneumonia can be aggravated by superimposed bacterial infections, such as Streptococcus 
pneumoniae (63, 64). Those who are hospitalized may require oxygen supplementation or 
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mechanical ventilation (61) because RSV infection induces lung pathology by forming 
syncytia in the respiratory tissue (65). The preservation of the respiratory system’s 
anatomical structure is essential for respiratory functions. 
 Immune response during RSV infection 1.8.
RSV replicates, assembles new virions and spreads throughout the respiratory tissue at the 
expense of infected cells. Successful virus replication also relies on the virus taking over the 
host cell metabolic machinery; this can lead to host cellular starvation and cause tissue injury. 
Any microbe, including RSV which crosses the host physical barriers such as the skin and 
mucosal lining of the body is confronted by the innate immune response which is the first line 
of defence against microbes (Figure 1.3a) (16). Immune and epithelial cells detect viral 
infection using pattern recognition receptors (PRR) such as Toll-like receptors (TLR) and 
nucleotide-binding oligomerization domain (NOD) like receptors (60, 66). PRR initiate host 
cellular responses in infected cells that inhibit virus replication, and secrete cytokines such as 
type I interferons which also inhibit RSV replication. As part of this intrinsic mechanism, 
RSV infected cells may undergo apoptosis, which halts the virus replication cycle and 
simultaneously initiates an inflammatory cascade in the respiratory tissue (67, 68). RSV 
infection may cause damage to the respiratory tissue either by viral replication or 
exacerbation of the host immune system, which itself may cause tissue damage. Immunity 
following first infection is incomplete and subsequent RSV infection can occur albeit usually 
milder. Hence RSV is characterized by recurrent infections throughout life, but which can 
also result in serious complication in older immune suppressed individuals (69). 
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         (a) (b) (c) 
Figure 1.3. Early host immune response during RSV infection  
(a) The RSV enters the host through the respiratory tract. Tissue macrophage and dendritic cells are constantly protecting the 
epithelial tissue beneath the mucosal lining. Neutrophils, lymphocytes, monocytes, erythrocytes, platelets and other blood 
components normally circulate in the blood vessels. (b) RSV adheres to and invades epithelial tissue. Resident macrophages, 
dendritic and epithelial cells release cytokines and other inflammatory mediators. Cytokines diffuse into the respiratory tract, blood 
circulation and simultaneously trigger the endothelial tissue to become permeable to blood contents. Epithelial tissue inflammatory 
state is successfully established. (c) Monocytes, neutrophils and lymphocytes adhere to the endothelial tissue and migrate from the 
blood towards the infection site in response to the cytokine gradient. Upon arrival at the infection site, the leukocytes interact together 
to mount an immune response that will be effective at clearing the infection. In severe cases, the RSV will continue to replicate and 
cause nearby epithelial cell membranes to fuse and form syncytia, resulting in tissue pathology. Produced by Mahlodi P Montlha. 
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 Cytokines implicated in severe RSV infection 1.9.
Cytokine is a general term used to describe a group of immune system mediator proteins (70). 
Interleukins are mediators between leukocytes (71) and monokines, are secreted by 
phagocytic cells such as macrophages and monocytes (72). Chemokines are secreted by 
leukocytes or other cells and cause migration of leukocytes towards the site of secretion (73) . 
Lymphokines are secreted by activated lymphocytes, especially helper Th1 cells-1 and Th2 
cells (72). Cytokines have low molecular weight and a short half-life. They act as chemical 
messengers between the innate and adaptive immune systems (74, 75). 
Cytokines form part of a large signalling cascade network which involves other proteins.  The 
signals generated can protect host cells from infection and/or induce damage to host cells. 
Cytokines may have agonist, antagonist, or synergistic cellular effects (76). The most 
important characteristic of cytokines is that they are produced when they are needed; this is 
crucial to immune system regulation. Cytokines are produced by cells of both the innate and 
adaptive immune system including epithelial cells (77). The same cytokine molecule may 
have pleiotropic effects, and can be secreted by several cell types and also act on a variety of 
cell types, resulting in individual responses accordingly to the target cell. Cytokines of 
different origins and compositions may have overlapping functions, i.e. they may be partially 
redundant (76). 
In broad terms cytokines can be largely classified into mediators of innate or adaptive 
immunity and stimulators of haematopoiesis (78). Within the mediators of innate and 
adaptive immunity groups there are pro-inflammatory and anti-inflammatory cytokines 
(Figure 1.4). Pro-inflammatory cytokines of the innate immunity include interleukin (IL), -
1α, IL-1β, TNF-α, IL-12 and interferon gamma (IFN-γ) (79). Innate cells such as 
macrophages usually produce IL-10 as an anti-inflammatory cytokine (80), and chemokines 
such IL-8, macrophage inducing protein (MIP-1α), monocyte chemo attractant protein (MCP-
1), and Regulated on Activation, Normal T cell Expressed and Secreted (RANTES) as 
attractants of different cell types from the blood circulation or lymph tissues (81). IFN-γ, 
TNF-α, and IL-10 are also produced by cells of the adaptive immunity.  
The adaptive immunity pro-inflammatory cytokines are mostly produced by T-cells 
expressing the CD4+ or CD8+ markers, Th and cytotoxic T (Tc) cells (82). Helper T cells are 
subdivided into Th1, Th2, Th17 and T regulatory (Treg) cells on the basis of the cytokines 
they produce (83, 84). Th1-cytokines such as TNF-α, IFN-γ, and IL12 are crucial in initiating 
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cell mediated cytotoxicity immune responses largely facilitated by natural killer cells, natural 
killer T-cells, γδ T-cells and Tc cells (84). Th2-cytokines that are important in mediating pro-
inflammatory associated with humoral immunity include IL-4, IL-13, IL-5 and IL-9 (84). IL-
10 and transforming growth factor β (TGF-β) are classic anti-inflammatory cytokines of the 
adaptive immunity secreted mainly by Tregs (84, 85). Th17 cells produce IL-17 and are 
maintained by the presence of IL-23 which are strong pro-inflammatory cytokines associated 
with autoimmune diseases and maintain mucosal lining (86). Stimulators of haematopoiesis 
include granulocyte colony stimulating factor (GM-CSF) which stimulate the growth and 
differentiation of progenitors into monocytes and macrophages (87). These cytokines have 
been well studied during RSV infection and some have been associated with more severe 
outcomes. Table 1.1 shows a summary of the cytokines implicated in RSV-LRTI which the 
present study investigated. 
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Figure 1.4. Cytokine categories 
Cytokines can be grouped as mediators of innate or adaptive immunity and stimulators of haematopoiesis.
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Table 1.1. Cytokines implicated in RSV disease 
Cytokine Function Reference 
IFN-γ 
  
  
 Low serum levels measured in cases with mild disease 
 Levels increase with severity  
(88) 
 High plasma levels of IFN-γ in infants with mild disease 
compared to severe and control groups. 
 High levels of IFN-γ and IL-12 reduce viral replication  
(89) 
IL-1α 
  
 High concentration within nasopharyngeal aspirate was 
found to be related to severe disease  
 Recruit neutrophils to the infection site 
  
 (90-92) 
IL-β 
 Released by endothelial, monocytes and macrophages 
during RSV infection  (70) 
IL-4  Produced by peripheral T cells of infants with RSV  (88) 
IL-5 
  
  
  
 Detected in plasma of infants with severe disease 
 Recruits and prolongs the survival of eosinophils 
 Produced by CD4+ T cells that recognise RSV 
attachment G protein 
 Acts in concert with IL-4 and IL-10 to promote Th2 
immune responses 
 (93, 94) 
  
  
  
IL-6 
  
  
  
 Enhances lymphocytes to differentiate into IL-17 
producing cells during primary RSV infection 
 Increased levels found in nasopharyngeal aspirate of 
infected infants; enhances disease pathogenesis 
 Produced by alveolar macrophages and airway epithelial, 
and induces  mucosal B cells 
  
  
 (95, 96) 
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IL-8 
  
  
  
  
 Increased in nasal secretion during infection 
 Secretion by epithelial cells is readily induced by RSV 
 Attracts inflammatory immune cells that produce MCP-1 
and MIP-1α 
 Recruit neutrophils, eosinophils, T cells to the infection 
site 
 Increased plasma level observed in severe disease  
(91, 95, 
97-99) 
  
 
  
IL-9 
  
  
 Stimulates mucus secretion and augment inflammatory 
response 
 Involved in pathogenesis of severe infection 
 Secreted by neutrophils 
 (100) 
 
  
  
IL-10 
  
  
  
 Anti-inflammatory cytokine 
 Up regulates anti-inflammatory mediators 
 Levels increase during infection   
 Up regulation correlated with IFN-γ  
  
  
 (70, 101) 
 
  
IL-12 
  
  
  
 Increased levels of IL-12 together with IFN-γ initiate 
defence mechanisms against RSV 
 Serum levels are increased in mild cases, suggesting a 
protective role 
 Production of IL-12 decreases during acute phase of 
infection as a result from viral inhibitory effects 
 Production also decreases in severe cases  
(89, 102, 
103) 
  
IL-13 
  
 Stimulate IgE synthesis 
 Activates and cause migration of eosinophils and 
basophils to infection site  
(104, 105) 
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MCP-1 
  
  
  
 Increased in nasal secretion during infection 
 Recruits monocytes during inflammation including 
neutrophils, basophils, monocytes, NK Cells and 
activated T cells 
 Important in pathogenesis of severe infection 
  
 (106, 107) 
  
  
MIP-1α 
  
  
 Increased quantities measured from severe cases 
 Initiates inflammatory response during infection  
 Induces mediator (histamine, cysteinyl leukotrienes) 
releases from basophils 
  
 (108-110) 
  
RANTES 
  
 Increased in nasal secretion during infection 
 Secretion by epithelial cells is readily induced by RSV 
  
 (111, 112) 
TNF-α 
  
  
  
  
 Produced by alveolar macrophages and airway epithelial 
cells 
 Increased levels observed in nasopharyngeal aspirates of 
severe infants compared to control 
 Induces the production of IL-6 
 Recruit neutrophils and mononuclear cells to infection 
site 
 Associated with development of asthma 
  
  
  
 (96, 113) 
  
 
1.9.1. Intruder alarms: TNF-α, IL-1 β and IL-1α 
Tumour necrosis factor is a classic pro-inflammatory cytokine, is produced by activated 
antigen presenting cells such as macrophages, dendritic and B-cells in response to infection. 
Exposure of endothelial cells to TNF-α results in the expression of adhesion molecules like 
P-selectin, and causes the endothelial tissue to be permeable to the contents in the blood 
circulation (114). In most cases, TNF-α is the first cytokine to signal nearby cells of an 
infection and begins to co-ordinate the response of these cells. TNF-α is an important 
antiviral cytokine. The expression of TNF-α is normally followed by that of IL-1β which 
further augments local inflammation by inducing endothelial cells to express adhesion 
molecules that facilitate the migration of leukocytes from the pulmonary blood circulation to 
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the inflammation site (chemotaxis, Figure 1.3c) (79, 115).  These immune cells will further 
contribute to the secretion of more pro-inflammatory or anti-inflammatory proteins at the 
infection site (92, 116). A recent study evaluating nasopharyngeal aspirates (NPA) from RSV 
infected infants reported IL-1β as a pro-inflammatory biomarker for disease severity (117).  
Interleukin 1α is also a pro-inflammatory cytokine mainly produced by activated 
macrophages or by infected epithelial cells. In an elegant experiment, Chang et al. (2003) 
incubated endothelial cells with a cytokine-supernatant cocktail collected from an epithelial 
cell line inoculated with RSV. After treating the supernatant with UV radiation to attenuate 
the virus, the presence of IL-1α among other cytokines was investigated. This study observed 
that IL-1α induced the expression of adhesion molecules on endothelial cells. When IL-1α 
was blocked with a specific antibody, the endothelial cells failed to express adhesion 
molecules on their surface. This  indicated that IL-1α facilitated a cascade that leads to 
migration of leukocytes from the pulmonary blood vessels into the airway spaces or lung 
tissue (92). 
1.9.2. Anti-virus: TNF-α and IFN-γ  
A study by Rutigliano and Graham (2004) demonstrated that TNF-α in addition to being an 
intruder alarm also played a role in clearing RSV infected cells in the early stages of infection 
(118). Elevated levels of interferon gamma (IFN-γ), a Th1 cytokine crucial in immune 
modulation during viral infection (119), have been reported to have anti-viral activity against 
RSV by stimulating the activity of Tc and natural killer cells. IFN-γ  has also been implicated 
with RSV-associated wheezing (119). Studies evaluating IFN-γ association with severity 
have been contradictory; low levels of this cytokine have also been associated with the 
susceptibility to severe RSV disease (89). Kim et al. (2012) found that increased airway 
levels of IFN-γ during RSV bronchiolitis was associated with eosinophil inflammation and 
positively correlated with RANTES expression (119).   
1.9.3. Mediators of attraction: RANTES, IL-8, MIP-1α and MCP- 1 
Yamada et al. (2011) investigating the effect of Th1 and Th2 cytokines in an epithelial cell 
line found that the levels of these cytokines before RSV infection were important in the 
regulation of transcription of genes involved in the inflammatory response during RSV 
infection (120). In earlier studies, Domachowske et al. (2001) and Zhang et al (2001) 
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reported that RSV infection induced epithelial cells to secrete cytokines and chemokines 
involved in apoptosis responses, including IL-8, RANTES, MIP-1α, and MCP-1 (98, 121).  
A study by Smyth et al. (2002) evaluated the nasopharyngeal secretions from infants infected 
with RSV, and identified increased concentrations of IL-8 and RANTES  as risk factors for 
severe disease (122). According to that study during RSV bronchiolitis, increased levels of 
IL-8 resulted in accumulation of neutrophils into the alveolar space; and in most cases were 
directly correlated with increased white blood cell count and disease severity (122). RANTES 
also known as CCL5 has been detected in the nasopharyngeal secretions of infants with RSV 
infection and has been reported to recruit eosinophils cells to the infection site (123) resulting 
in airway mucosa inflammation (124). In vitro studies have also demonstrated that RSV 
induces alveolar macrophages to secrete RANTES (125). 
During RSV-associated LRTI there is an increase in production of MIP-1α by the epithelial 
cells; this phenomenon has been observed in children with severe disease (126). It is believed 
that MIP-1α attracts monocytes, lymphocytes, mast cells, basophil and eosinophil cells, and 
possibly induces their degranulation to inhibit RSV replication (108, 127). An in vitro study 
has also shown that eosinophils can directly destroy extracellular virions (128). 
MCP-1 also known as CCL2 is a monocyte chemokine that induces Th1 and Th2 
inflammation. Numerous studies have found increased levels of MCP-1 both in vitro and in 
mice following RSV infection (125, 129). Clinical studies also found that levels of MCP-1 
were elevated in nasopharyngeal aspirates during RSV infections, and were directly 
associated with disease severity (117). The expression of MCP-1 in cell lines that were 
previously primed with Th2 cytokines enhanced RSV replication, demonstrating that MCP-1 
played a crucial role in RSV-host interaction pathogenesis (130). 
1.9.4. Stimulators of cell growth and differentiation: IL-4, IL-13, IL-5 and IL-9 
Interleukin 4 is a Th2 cytokine mainly produced by Th2 cells and macrophages. It mediates 
the development of new Th2 cells, and also stimulates the growth of differentiated Th2 cells 
that will activate B cells to produce antibodies (131). IL-4 promotes immunoglobulin isotype 
class switching, including to IgE.  
IL-13 functions partially overlap with those of IL-4, including stimulating B-cell growth. 
Animal studies found that IL-13 was associated with reduced disease severity by preventing 
severe weight loss in RSV infected mice, and this was contradictory to humans (104).  
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Interleukin 5 is also produced by mast cells and Th2 cells (132); it stimulates the growth and 
differentiation of B cells, and activates differentiated eosinophils to release microbial toxic 
proteins (133, 134). 
Interleukin 6 is a Th2 cytokine important in haematopoiesis. It facilitates the transition from 
innate immune response to a state of memory immune response by promoting the formation 
of plasma cells from B cells (135). Studies conducted by Becker et al. (1991) found that the 
interaction of RSV with alveolar macrophage led to the secretion of mediators which induced 
respiratory system epithelial cells to secrete IL-6 and IL-8 (136). In support to this, Jones et 
al. (2005) also suggested that alveolar macrophages in the presence of IL-6 and IL-8 inhibit 
RSV infection and support cellular and humoral immunity (135). 
Interleukin 9 has pleiotropic effects; it has Th2-like functions and is important in stimulating 
activated Th2 cells to proliferate. Additionally, its secretion enhances the production of IgE 
from B cells and promotes the proliferation of haematopoiesis progenitors and mast cells. IL-
9 has a synergic relationship with IL-1β and TNF-α. The latter cytokines act independently to 
stimulate the release of IL-9 by T-cells but this is not observed when both IL-β and TNF-α 
are present (115). IL-9 has been shown to be released by peripheral human blood eosinophil 
and modulates antiviral immunity during RSV infection by regulating T and B cells 
responses (137).  
1.9.5. Immune regulator: IL-10 
Interleukin 10 is an anti-inflammatory cytokine mainly produced by activated Th2 cells and 
macrophages. IL-10 can inhibit co-stimulatory signals required at the immunological 
synapse, the expression of human leukocytes antigen class II and cytokine production by 
activated macrophages. This total effect can regulate the strength of the immune response. 
IL-10 production may also inhibit the production of IFN-γ secreted by Th1 cells and thus 
favour Th2 cells to mount an immune response (138). When analysing nasopharyngeal 
aspirates of RSV infected infants, Murai et al. (2007) observed a synergistic role between IL-
10 and RANTES. The levels of IL-10 and RANTES were elevated in RSV infected infants 
compared to the RSV uninfected group but association with severity was not reported (139). 
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 Cytokines as potential biomarkers of RSV disease severity  1.10.
During RSV pathogenesis, the levels of several host cytokines have been shown to be either 
increased or decreased; however whether cytokine levels have a protective role in disease 
progression remains controversial (16). There is a growing interest in evaluating cytokines as 
biomarkers of disease severity. A biomarker in this context is any measurable molecule (such  
as cytokines, complex carbohydrates, growth factors, lipids or hormones) that can be 
distinctively associated with a physiological change or pathological process (140). 
Biomarkers have been successfully used for prognosis and diagnosis of some autoimmune 
diseases, cancers and infectious diseases. These molecules can be detected and quantified 
from biological samples such as plasma, serum, nasopharyngeal aspirates or cell culture 
supernatant (141). Perturbations of cytokine levels are sometimes associated with a 
pathological response. Understanding the complex cytokine environment can serve as 
biomarker for disease severity (142, 143), and guide vaccine design and medical intervention 
strategies (144).  
In South Africa cytokines associated with severe RSV infection have not been studied 
previously, and are most likely different from those documented from the Americas, Europe 
or Asia. Sub-Saharan Africa has a high burden of HIV and other comorbidities, as well as 
more prevalent malnutrition, all of which may play a role as risk factors of severe RSV 
infection. Cytokines can be quantified with immunoassays such as enzyme-linked 
immunosorbent assay (ELISA) (145) and Luminex assay (146). Luminex assays use 
microscale “ELISAs” on magnetic beads to detect and quantify molecules using a flow 
cytometer based detector (147). It allows evaluation of multiple cytokines simultaneously per 
experiment in contrast to single-plex ELISA (143, 146, 147).  
 Study rationale 1.11.
Many infants with RSV-LRTI develop mild symptoms and do not need prolonged 
hospitalization or therapeutic support. Other infants after RSV infection they progress to 
severe illness necessitating prolonged hospitalizations and even intensive care admission. 
There are currently no biomarkers able to predict the disease progression and outcome of 
infants with RSV-LRTI. Host immune responses during the progression of RSV-LRTI could 
be important in determining the severity and outcome of the disease, and might serve as 
potential biomarkers. Several studies have in the past reported associations between cytokines 
and severe RSV-associated LRTI. The majority of the cytokines associated with RSV-LRTI 
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severity have been studied in non-African populations, to our knowledge this was the first 
study to evaluate these cytokines in African infants. Additionally we wanted to evaluate if the 
cytokines can predict severe RSV-associated LRTI in the South African population.  
Recent studies by Nédélec et al (2016) and Quach et al (2016) have shown that the African 
population have a strong inflammatory response towards pathogens as compared to the 
European population (148, 149). This shows there is a need for the cytokines to be studied in 
the South African population, rather than incorporating into our intervention strategies the 
cytokine results obtained from populations of different ethnicity. 
The aim of this study was to measure the levels of key cytokines previously implicated in 
RSV-LRTI and assess their potential as biomarkers for discriminating severe from  mild 
RSV-associated LRTI in infants <12 months during the annual RSV epidemic season. 
Additionally we wanted to understand the immune response etiology involved in RSV-LRTI 
or mediating RSV-LRTI severity.  
Study Objectives  
a) Evaluate any association between RSV-associated LRTI severity and cytokine 
levels in the blood and nasopharyngeal aspirates.   
b) Compare the cytokine profile in RSV associated LRTI cases to controls 
children without evidence of respiratory tract infection. 
c) Evaluate the correlation between cytokine levels in the blood and in 
nasopharyngeal aspirate samples among RSV-LRTI cases. 
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Chapter 2: Materials and Methods 
 Ethics clearance and approval 2.1.
Permission to conduct this study was obtained from the Human Research Ethics Committee 
(HREC) of the University of the Witwatersrand-Medical, Johannesburg, South Africa, with 
the clearance number: M160872. The clearance certificate is included as appendix A (Figure 
1). This study was carried out according to the HREC guidelines. Signed informed consent 
was obtained from the parents or legal guardians of the participants of the study “Surveillance 
on pathogen-specific causes of pneumonia and diarrhoea hospitalization in children” 
(abbreviated as the “BoSS” study) before enrolment. The main study was an active 
surveillance study evaluating the burden of different respiratory pathogens such as RSV, 
Bordetella species, influenza and human metapneumovirus in hospitalized children. Clinical 
records and laboratory specimens from study participants were identified by a unique study 
identity number allocated during enrolment. Hard copy records were stored in a secured 
place, while electronic capturing of information was carried out with coded numbers only. 
 Study population and inclusion/ exclusion criteria 2.2.
The study was conducted at Chris Hani Baragwanath Academic Hospital (CHBAH) located 
in the Soweto area in the city of Johannesburg, Gauteng, South Africa 
https://www.chrishanibaragwanathhospital.co.za/.  
Participants were enrolled from 15 March 2016 to 29 August 2016. This study included 
infants between 0-12 months of age who were admitted at CHBAH. Potential case 
participants were identified as infants presenting with lower respiratory tract infection 
(LRTI). A convenience sample of control participants were infants scheduled for elective 
surgery with no respiratory symptoms or respiratory illness. Inclusion criteria for cases: 
a. Child under 12 months of age admitted to the paediatric medical ward at CHBAH AND 
b. In children under 3 months of age: Any child with diagnosis of suspected sepsis or 
physician diagnosed LRTI irrespective of signs and symptoms  
c. In children above 3months of age: Admitting diagnosis of acute pneumonia or other 
physician diagnosed LRTI  
AND  
Symptom onset less than 7 days prior to hospitalisation 
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Soweto has a high prevalence of HIV. As a consequence HIV infected and exposed infants 
were included in this study. Table 2.1 below summarises the HIV status of the control infants 
and RSV cases.  
Infants were excluded from the study if they were receiving corticosteroid, had congenital 
heart disease or had an underlying medical condition at the time of enrolment. Enrolled 
infants that met case definition but tested positive for other respiratory pathogens (Bordetella 
species, influenza and human metapneumovirus) other than RSV were also excluded from the 
study. For both case and control infants who had no paired plasma and NPA samples were 
excluded. Figure 2.1 shows the study design. 
 After the consenting progress Respiratory and Meningeal Pathogens Research Unit 
(RMPRU) study staff, administered the study questionnaire and collected the study related 
samples. Following collection, samples were immediately transported on ice to the RMPRU 
laboratory.   
Table 2.1 HIV status of the control infants and RSV cases 
HIV Status (N) Control  Mild  Severe  
  n=31 n=89 n=113 
HIV Uninfected    
 
  
Unexposed 22 73 82 
Exposed  9 9 10 
Unknown exposure  - 2 9 
HIV Infected 0 5 12 
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Figure 2.1. Study design 
Participants that were enrolled and subsequently excluded from the current analysis are shown in red. 
The samples were excluded as a result of unpaired sample, insufficient plasma volume, uncaptured 
clinical data before cytokines were measured. The blue rectangles show the number of participants 
who had RSV coinfections and were also excluded.  
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 Scoring RSV-LRTI severity 2.3.
Infants with RSV infection were divided into two groups: i) mild and ii) severe disease, based 
on the previously described Respiratory Index of Severity in Children (RISC) Score (150). 
The first group included hospitalized infants with mild LRTI who had a RISC score from -2 
to 3 inclusive. The second group included infants with severe LRTI with a RISC score above 
3. HIV-unexposed-uninfected and HIV-exposed-uninfected infants were scored using RISC 
criteria for HIV-uninfected patients. HIV-infected infants were scored using the RISC score 
criteria for HIV-infected. The clinical RISC score algorithm is included as appendix C. 
Although there are other clinical scores that have been used to score RSV disease severity 
(151, 152), the RISC score was developed in the context of South African infants hospitalized 
for LRTI, incorporating HIV-infection and nutritional status. 
 Sample collection 2.4.
Nasopharyngeal swabs (NPS) and nasopharyngeal aspirates (NPA) were collected into 
universal transport medium (UTM; Copan, Brescia, Italy) during hospitalization – of the 
participants. NPS or NPA were used for testing of respiratory pathogens including RSV A 
and B using an in-house 1-step multiplex real time polymerase chain reaction (PCR) assay. 
Only NPA were collected from control participants. Total nucleic acids were extracted from 
NPS or NPA using an automated nucleic acid extraction machine, NucliSENS® easyMAG® 
(BioMerieux, France). The in-house PCR assay was setup to test for RSV A and B, influenza 
A and B, human metapneumovirus and Bordetella species. Positive controls for pathogens as 
well as RSV A and B were included in each multiplex PCR reaction, and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) gene was used as a human internal control. Children 
who tested positive for RSV A or B in the PCR (i.e. quantitation cycle value ≤35) were 
classified as cases. RSV cases had no PCR confirmed coinfection with other pathogen that 
we investigated for; i.e. as we tested limited number of respiratory pathogens, we cannot be 
conclusive that we excluded all coinfections. Surgical participants who tested positive for any 
of the respiratory pathogens tested in the PCR assay were excluded from the study. 
Furthermore, during RSV season (when approximately 70% of LRTI are due to RSV), 
children enrolled into the main BoSS study also consented to have a blood draw (collection 
of 2-3 ml). All control children had a blood draw at enrolment. Paired RSV (A or B) positive 
NPA and whole blood samples were used to evaluate the cytokine profile of the hospitalized 
infants.  
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2.4.1. Plasma sample preparation 
Approximately 2-3 ml of whole blood was collected into ethylene-diamine-tetra-acetic-acid 
(EDTA) containing tubes following venepuncture. EDTA is an anticoagulant that maintains 
whole blood in liquid form and protects easy to denature blood components such as cytokines 
(153). Following blood collection, the tube was inverted several times to mix whole blood 
and EDTA. Samples were transported to the RMPRU laboratory in a cooler bag for 
processing within 1 hour.  
Upon arriving at the laboratory, samples were verified not to have haemolysed; haemolysed 
samples were not used for the experiment. Whole blood samples were centrifuged at 3320 
revolutions per minute (rpm) for 15 minutes at 4˚C using a bench top centrifuge (Eppendorf, 
United kingdom) to separate the whole blood sample into plasma, buffy coat, and 
erythrocytes layers. The plasma, the first layer, was transferred into a sterile polypropylene 
tube, and centrifuged again at 3320 rpm for 10 minutes at 4˚C to completely remove 
remaining precipitates and platelets. Approximately 250 µl of plasma was aliquoted into each 
of the three cryovials for single-use to prevent freeze thaw cycles. Plasma samples were 
stored at -70˚C until further testing. 
2.4.2. Nasopharyngeal aspirate sample preparation 
Nasopharyngeal aspirates were collected by introducing a suctioning tube into the 
nasopharynx and approximately 1.5ml of sterile saline was instilled. The suctioning tube was 
connect to mucous trap and fitted to a syringe. The aspirate was suctioned and collected into 
a sterile tube containing 3ml of Universal transport medium (UTM) (see below for details). 
The samples were immediately transported to RMPRU laboratory for processing within 3 
hours. NPA were centrifuged at 3320 rpm for 15 minutes at 4˚C to pellet the cells using a 
bench top centrifuge (97). The supernatant was aliquoted into three cryovials to avoid 
unneeded thaw cycles of samples as this may damage the cytokines. The supernatant was 
stored at -70˚C until testing.  
Universal transport medium is an isotonic solution, non-toxic to human cells and maintains 
the viability of viruses; it is formulated with Hank’s balanced salt solution, supplemented 
with bovine serum albumin, sucrose, cysteine and glutamic acid. Furthermore UTM contains 
the antibiotics vancomycin, amphotericin and colistin which minimise the growth of 
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competing yeast, fungi and bacteria. UTM is buffered with HEPES buffer at pH 7.3 ± 0.2 at 
room temperature and  contains phenol red to indicate any pH deviation (154). 
 Quantitative measurement of cytokines using commercially available Luminex 2.5.
assay 
A commercial custom made multiplex bead immunoassay “Human Cytokine 15-Plex” Kit 
Catalogue Number: LHB001M and LCP000SA (Invitrogen, Life Technologies Corporation, 
California USA) was used to measure the cytokine levels in the study samples. The kit was 
designed to detect and measure the following human cytokine panel: IFN-γ; IL-1α; IL-1β; IL-
4; IL5; IL-6; IL-8; IL-9; IL-10; IL-12(p70); IL-13; MCP-1; MIP-1α; RANTES; TNF-α These 
cytokines were selected based on the literature (Table 1.1). This kit included: validated 
cytokine-specific antibody bead concentrate, wash solution, biotinylated antibody and biotin 
diluent, 15-Plex cytokine standards (concentrations shown in Table 2, appendix D), 
streptavidin-PE concentrate and diluent, assay diluent, incubation buffer, and a 96-well flat 
bottom plate. All reagents were stored at 4˚C and brought up to room temperature before use. 
Cytokines levels were measured and quantified on a Luminex xMAP instrument (Bio-Rad 
Laboratories Inc., USA). Step-wise details of reagent preparations are reported in appendix D 
and for Luminex® instrument setup are reported in appendix F. Kit manufacturer instructions 
were closely followed during the study and amendments were noted and reported. All assays 
were conducted at RMPRU. 
2.5.1. Principles of Multiplex Bead Immunoassays with Luminex 
Multiplex bead immunoassays allow simultaneous detection of multiple cytokines from one 
sample using fluorescent dyed microspheres. The principles of this technique are based on 
sandwich ELISA. The microspheres are magnetic beads each containing a unique spectral 
property that permits discrimination of one bead from another. Magnetic microspheres were 
covalently cross-linked to a monoclonal capture antibody; the antibodies are specific for each 
cytokine of interest. 
A flat bottom 96-well plate, designed for use with a magnetic handheld washer, was coated 
with 25µl of 1X magnetic microspheres conjugated with primary antibodies against 15 
cytokine panel. The coated plate was washed twice with 200µl of 1X wash solution using the 
handheld magnetic washer (Bio-Rad Laboratories Inc., USA). Incubation buffer (50µl) was 
added to all wells. This was followed by the addition of test samples (50µl of plasma or 70µl 
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of NPA diluted with 50µl of assay diluent) or cytokine standards of known concentrations in 
assay diluent. The first 2 wells of the plate served as blank samples and no test sample or 
cytokine standard was added. Cytokine standard, test and blank samples were setup in 
duplicates. This multiplex assay suspension was incubated at room temperature in the dark on 
an orbital shaker (Daigger Scientific, USA) (500 rpm) for 2 hours. This allowed the cytokines 
of interest in the samples to react and bind with the specific primary antibodies coupled to the 
magnetic microspheres. The incubation period was followed by a series of washes (always 
using the handheld magnetic washer appendix E) to remove unbound cytokines.  
1X biotinylated secondary detection antibody (100µl) was added to the plate and, incubated 
at room temperature in the dark on an orbital shaker for 1 hour to react with the cytokine 
monoclonal capture antibody. This resulted in a sandwich complex. The biotinylated 
secondary antibody serves as an amplification step that intensifies the detection signal and 
allows the visualization of the antibody binding to the cytokine of interest. 
This was followed by washing off unbound biotinylated detection antibody and adding 100µl 
of 1X streptavidin conjugated to phycoerythrin fluorescent protein (SA-PE conjugate) to 
form a detection complex which was incubated at room temperature in the dark on an orbital 
shaker for 30 minutes. At the end of this incubation period the liquid was decanted and the 
assay plate was washed three times. 1X wash solution (150µl) was added to each assay well, 
covered and incubated in the dark on an orbital shaker at 500 rpm for 3 minutes. The plate 
was uncovered and loaded onto the Luminex 200 platform and the assay was acquired to 
quantify the specific cytokines.  
The biotin SA-PE conjugate is the preferred detection method for molecules such as 
cytokines as they are occasionally expressed at low levels that cannot be detected using solely 
labelled antibody. The signal amplification takes advantage of the strong affinity that 
streptavidin protein has for the tetrameric biotin. Four SA-PE conjugates bind to a single 
biotinylated antibody and the phycoerythrin fluorophore serves as the reporter signal. 
Cytokine standard proteins provided with the kit generated a range of concentrations during 
the assay to allow extrapolation of cytokine levels within the test samples. 
During data acquisition the multiplex assay suspension was drawn from the plate into the 
Luminex instrument. A red laser of 635nm interrogated the spectral property of each 
microsphere to identify the cytokine, while the green laser of 532nm simultaneously excites 
PE linked to streptavidin to generate a reporter signal that is detected by the photomultiplier 
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tube (PMT). Bio-Plex Luminex instrument employs modified flow-cytometry-based laser 
technology and is fitted with a high speed digital processor to generate a comprehensive data 
output. The Bio-Plex Manager Software version 5 (Bio-Rad Laboratories Inc., USA) reports 
the data as mean fluorescence intensity (MFI) and automatically makes the conversion to 
concentration (pg/ml). The concentration of each cytokine is proportional to the MFI of the 
PE (147).  
2.5.2. Standard curve dilution matrix for NPA assays 
Tabarani et al (2013) studying cytokines in NPA from children infected with RSV causing 
severe illness also used a commercial multiplex bead immunoassay similar to that used in our 
study (117). The kit used in this study was validated and optimised for cytokine detection 
from serum, plasma, and tissue supernatant; but it was not optimised for cytokine detection in 
NPA. Certain aspects of the kit had to be adjusted for detection of cytokines from NPA 
collected into UTM. During NPA sample assay, the standard vials were reconstituted with 
50% assay diluent (provided by manufacturer) and 50% UTM. This facilitated the diluted 
standards to match the NPA samples dilution, since the NPA was collected into UTM. Both 
the standards and the NPA samples were therefore diluted in the identical buffer preparation. 
2.5.3. Estimation of dilution factor introduced during NPA collection 
Collection of NPA by direct aspiration without using any fluid does not provide enough 
samples to perform clinical assays. Also fluid such as saline solution is used during aspiration 
to reduce discomfort associated with aspiration of nasal secretions. While this favoured 
accumulation of adequate assay volume; there is an unknown dilution factor which is 
introduced during NPA collection. It is important to correct for this dilution factor when 
reporting cytokine concentrations to prevent the distortion of results with clinical significance 
(155). During this study, the NPA was collected into 3ml UTM using 1.5ml 0.9% saline. The 
dilution factor that was introduced during NPA collection was estimated to be 1.25-fold using 
the formula below:  
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𝐼𝑛𝑡𝑟𝑜𝑑𝑢𝑐𝑒𝑑 𝑁𝑃𝐴 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 =  
𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑓𝑙𝑢𝑖𝑑
𝑡𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 − 1 𝑚𝑙
  
𝐸𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 𝑡𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 = 1.5 𝑚𝑙 𝑠𝑎𝑙𝑖𝑛𝑒 + 0.5 𝑚𝑙 𝑁𝑃𝐴 + 3 𝑚𝑙 𝑈𝑇𝑀 = 5 𝑚𝑙 
𝐼𝑛𝑡𝑟𝑜𝑑𝑢𝑐𝑒𝑑 𝑁𝑃𝐴 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 =  
5
5 − 1
 
𝐼𝑛𝑡𝑟𝑜𝑑𝑢𝑐𝑒𝑑 𝑁𝑃𝐴 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 = 1.25 𝑓𝑜𝑙𝑑 
This formula was obtained from Heikkenen et al. (1999) (155). 
During assay preparation 70µl of NPA was diluted with 50µl of assay diluent (provided with 
the kit) resulting in 120µl total volume of NPA loaded into assay wells. The dilution factor 
during sample loading into assay wells was estimated as 1.71-fold as shown by the equation 
below.  
𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑑𝑢𝑟𝑖𝑛𝑔 𝑠𝑎𝑚𝑝𝑙𝑒 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 =   
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓  𝑁𝑃𝐴 𝑖𝑛 𝑎𝑠𝑠𝑎𝑦 𝑑𝑖𝑙𝑢𝑒𝑛𝑡 
𝑁𝑃𝐴 𝑣𝑜𝑙𝑢𝑚𝑒
    
𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑑𝑢𝑟𝑖𝑛𝑔 𝑠𝑎𝑚𝑝𝑙𝑒 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 =
120 µl 
70 µl 
 
𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑑𝑢𝑟𝑖𝑛𝑔 𝑠𝑎𝑚𝑝𝑙𝑒 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 = 1.71 𝑓𝑜𝑙𝑑 
The total dilution factor of each NPA sample was approximated as 2.14-fold using the 
formula below.  
𝐹𝑖𝑛𝑎𝑙 𝑁𝑃𝐴 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
= (𝐼𝑛𝑡𝑟𝑜𝑑𝑢𝑐𝑒𝑑 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟)(𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑑𝑢𝑟𝑖𝑛𝑔 𝑠𝑎𝑚𝑝𝑙𝑒 𝑙𝑜𝑎𝑑𝑖𝑛𝑔)  
𝐹𝑖𝑛𝑎𝑙 𝑁𝑃𝐴 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 = 1.25 𝑋 1.71 
𝐹𝑖𝑛𝑎𝑙 𝑁𝑃𝐴 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 = 2.14 
The original cytokine concentration within the nasal cavity was obtained by multiplying the 
measured cytokine concentration by the Final NPA dilution factor. Similarly, during an assay 
preparation 50µl of plasma was diluted with 50µl of assay diluent (provided with the kit) 
resulting in 100µl total volume of plasma loaded into assay wells. The dilution factor during 
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sample loading into assay wells was estimated as 2-fold. The original plasma concentration 
was obtained by multiplying the measured concentration with 2-fold. 
 Assay reproducibility  2.6.
Inter assay variation was used determine the assay reproducibility. Inter assay variation for 
each plasma or NPA assay was determined by testing independent duplicate of prepared 
positive control samples. For each cytokine studied, a Levey Jennings quality control chart 
was generated to assess reproducibility of the results as per day to day variation.  
2.6.1. Preparation of positive control samples for plasma and NPA assays  
Whole blood used to prepare positive control samples for the plasma assay was donated by a 
single non-respiratory illness healthy adult. Ten vials with 100µl of plasma were prepared 
according to section 2.4.1. One plasma vial was thawed and included as plate control during 
each plasma assay. During the preliminary analysis of the results from plasma plate 1 (which 
was the first experimental plate), it was noted that some cytokines in the positive control 
sample were expressed at undetectable or reduced levels. As a consequence of these results, 
the remaining nine vials were retrieved from the freezer (handled on dry ice) and spiked with 
60µl of reconstituted cytokine standard of known concentration provided with the kit and 
returned for storage at -70˚C.  
NPA assay control samples were obtained from a single control participant. Ten vials of 
100µl NPA sample (prepared according to section 2.4.2) were spiked with 50µl of 
reconstituted cytokine standard of known concentration provided with the kit before being 
stored at -70˚C. One NPA vial was thawed and included during each NPA assay as plate 
control.  
2.6.2. Generation of Levey Jennings quality control charts 
Control samples for plasma and NPA spiked with known concentrations of cytokine 
standards were used to develop Levey Jennings quality control charts for each cytokine of 
interest as a measure of inter assay variability. The Levey Jennings rule assumes that the 
cytokines within the different vial aliquots of either plasma or NPA are stable and have 
minimum cytokine concentrations variation. Measuring cytokines from these single use 
aliquot samples during each assay over the period of the study has the ability to characterise 
technical errors or assay imprecisions (156). A sample of a given concentration would 
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naturally give different mean fluorescence intensity (MFI) values for different plates. 
Sometimes this difference is substantial, and it is corrected for by running a standard curve on 
every plate. MFI values for samples tested on different plates are expected to vary. It is 
therefore appropriate to generate the Levey Jennings on the output concentrations, which we 
expect to be similar for the same sample and not on the MFI. A quality control chart for each 
of the 15 cytokine was prepared for both plasma and NPA. The chart features the cytokine 
concentration on the y-axis and the assay plate number on the x-axis. A horizontal line was 
drawn at the cytokine mean, lower and upper limits. The limits included -2 and +2 standard 
deviation (?̅? ± 2SD), and ?̅? ±3SD which were calculated using the measures generated from 
all the plasma or NPA control samples. Finally the individual cytokine concentration from 
each assay plate was plotted on the chart. A stable and precise assay will produce cytokine 
concentration within the ?̅? ± 2SD lower and upper limit. An assay was rejected when 
cytokine concentration from the control sample exceeded the ?̅? ± 3SD control limits. 
Cytokine concentration from the control that exceeded ?̅? ± 2SD limits during an assay 
warranted further investigation before the assay results could be accepted or rejected. 
2.6.3. Levey Jennings assessment criteria for cytokine concentration exceeding ± 2SD 
A control sample with cytokine concentration between the ?̅? ±2SD and ?̅? ±3SD control limits 
was considered “suspicious” (156). Suspicious cytokine concentration obtained from control 
samples were analysed using the Levey Jennings assessment criteria. The criteria were 
applied to determine the need to reject and repeat the assay or to accept and report the assay 
results. An assay that was suspicious was tested for analytical systemic error with assessment 
criteria (explained below) and also tested for random error with assessment criteria. An assay 
violating any of these rules was rejected. According to Westgard (1981), the laboratory 
should decide which rules are significant for the assay and laboratory conditions (156). The 
assessment criteria that were applied during this study were the following: 
a) Systematic error test: 22SD 
The assay was rejected provided that 2 control samples from consecutive assays exceeded the 
?̅? ±2SD control limit. This rule was applicable even though a new aliquot of control sample 
(from same batch as previous assay run) was used in the consecutive assay. 
b) Systematic error test: 41S, 
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This rule rendered the assay to be rejected when four consecutive assay runs exceeded the ?̅?  
±1SD. This was acceptable since control samples of the same batch were used and there was 
no change in control sample batch during this study. In total there were 7 control samples for 
all plasma assays and 7 control samples for all NPA assays; therefore the rule could only be 
applied starting from the 5
th
 plasma or NPA assays.  
c) Random error test: 13S 
This is the optimal rejection criteria, ?̅? ±3SD control limit. A control observation that exceeds 
this limit was rejected and it was often due to undeterminable random analytical errors. The 
occurrence of this error should be an alert signal for assays to follow. 
In summary, these assessment criteria were used to assist resolve ambiguity when cytokine 
concentration in the control sample exceeded the ?̅? ±2SD control limit. 
2.6.4. Inter-assay precision  
The cytokine concentrations observed from the control samples were within the Levey 
Jennings control limits (appendix H) for most cytokines with exception for RANTES NPA 
plate 4. Figure 2.2 below shows inter assay variation for RANTES concentration over 7 NPA 
assays. This Figure shows that 6 out of 7 RANTES control observations were within the ?̅? 
±1SD control limit. The control observation on plate 4 exceeded however the ?̅?-2SD control 
limit. This warranted further interpretation before RANTES assay results from plate 4 were 
accepted or rejected.  
According to rule 22SD, the assay should be rejected provided that 2 concentration readings of 
the RANTES from 2 previous consecutive assays exceed the ?̅?±2SD control limit. The 
RANTES concentration on plate 2 and 3 observations were both within the ?̅?±2SD control 
limit, therefore this rule was not violated. The second test 41SD was also applied. 41SD rule 
renders the assay to be rejected when 4 previous consecutive assays runs exceed the ?̅?±1SD. 
This rule was also not violated because the concentration from plate 1, 2 and 3 were within 
the control limits. Additionally, test 13SD was also not violated because plate 4 concentrations 
did not exceed the optimal rejection criteria, ?̅?±3SD control limit. Taking all this into 
consideration the RANTES results on plate 4 were accepted as none of the Levey Jennings 
decision criteria tests were violated.  
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Figure 2.2. MFI Inter assay variability for RANTES over 7 NPA assays 
 Sensitivity of the Luminex assay and curve fitting algorithm 2.7.
The limit of detection (LOD) for each cytokine from either the plasma or NPA assay was 
calculated as the average of recorded blank sample MFI plus 2 standard deviations. The blank 
sample included all assay reagents but no plasma, NPA or standard (S) was added to it. MFI 
measured from the blank sample could have been a result of fluorophores not bound to 
specific target or from auto fluorescence of reagents used during the assay preparation.  
LOD was defined as the lowest cytokine concentration that could be reliably distinguished 
from the blank sample MFI. The upper limit of detection was not calculated; any sample with 
cytokine concentrations above S1 would had to be diluted and re-tested so that the 
concentration could be estimated within the reliable standard curve and later corrected for the 
dilution factor. During this study all samples’ cytokines were estimated within the standard 
curves. 
Table 2.2 depicts the LOD for cytokines. The average standard curve equation estimated by 
the Bio-Plex software manager was used to calculate the LOD concentration. The average 
MFI for the blank sample and standard deviation was calculated for the plasma and NPA 
assays. For each cytokine 2 standard deviations (+2SD) were added to the calculated average 
MFI of the blank sample. The LOD for each of the 15 cytokines was determined as the 
concentration at the “average MFI +2SD”, and it was obtained by solving the 5 parameter 
logistic regression (PL) curve equation for “X” following substitution of average “MFI 
(+2SD)” into the equation.  Bio-Plex software manager generated 5PL curve for each 
cytokine standard curve;  
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𝑦 = 𝑑 +  
𝑎 − 𝑑
[1 + (
𝑋
𝐶)
𝑏
]𝑔
 
Where: a = estimated response at zero concentration 
b = slope factor 
c = mid-range concentration (C50) 
  d = estimated response at infinite concentration 
  g = asymmetry factor 
  y = average MFI +2SD 
A 5 parameter logistic regression equation is a commonly used curve fitting method for 
estimating concentrations from a standard curve, i.e. plot of concentration versus 
fluorescence intensity response in immunoassays. The equation generates a well fitted curve 
model for standard curves that display symmetrical or asymmetrical MFI responses; Figure 
2.3 shows an example of a typical curve generated with the Bio-Plex Manager software.  
 
Figure 2.3. Example of Bio-Plex cytokine standard curve.  
From “Bio-Plex™ suspension array system” technical note  (157). 
 
Participants with cytokine concentrations that were below the LOD were assigned an 
arbitrary value that was ( 
1
2
 𝐿𝑂𝐷) of the specific cytokine to facilitate data analysis. The 
calculations of LOD for each cytokine in both the plasma and NPA assays are detailed in 
appendix G.   
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Table 2.2 Limit of detection for cytokines in plasma and NPA samples 
Cytokine Limit of detection (pg/ml) 
  Plasma NPA 
IFN-g 1.0 1.1 
IL-1α 8.9 7.8 
IL-1β 31.7 17.3 
IL-4 3.2 4.6 
IL-5 0.2 0.6 
IL-6 0.6 0.7 
IL-8 3.1 2.6 
IL-9 2.0 1.2 
IL-10 0.6 0.8 
IL-12p70 10.0 15.7 
IL-13 1.6 2.9 
MCP-1 31.8 35.1 
MIP-1α 6.3 6.7 
RANTES 6.6 5.3 
TNF-α 0.5 1.0 
 
 Plasma and NPA assay standard curves 2.8.
The protocol included with the detection kit suggested that the standard curves should be 
prepared as 7 series (S1 to S7) in three-fold dilution. This was followed for the first 4 plasma 
assay plates. Analysis of the results from the first four plasma assay plates showed that the 7 
series standard curve did not reach a plateau (estimated MFI response at infinite 
concentration) and had an exponential shape. The remaining 3 plasma assay plates and all 7 
NPA assay plates were assayed with a 9 series standard curve, which generated a sigmoidal 
shaped curve. Figure 2.4 shows an example of 7 and 9 series standard curve projection for IL-
5 from plasma assay; similar projections were observed for other cytokines. The bottom 
window of Figure 2.4 is a magnified lower end of 7 and 9 series standard curves respectively. 
The 7 series standard curve has a high MFI at S7 compared to the 9 series standard curve. 
The lowest IL-5 concentration that could be interpolated from the plasma samples with a 7 
and 9 series standard curve were 3.1pg/ml and 0.35pg/ml respectively.  
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Analysis of immunoassays using the Bio-Plex manager software can result normally in 3 
types of standard curve response; low-response, high response or sigmoidal response curve as 
shown in Figure 2.5 (157). The 7 series curves produced a high response curve (Figure 2.5b) 
which facilitated quantitation of high cytokine concentration from the samples. Cytokines 
that were expressed at low levels were reported by the Bio-Plex Manager software as under 
range. These could have been incorrectly assigned as below the LOD, had the standard curve 
not been diluted to S9.  
Sometimes a high response standard curve is not physiologically useful since most cytokines 
even when expressed at low concentrations have the ability to trigger a physiological 
response during disease (158). Analysis of the generated standard curves showed that this 
protocol adjustment yielded cytokine standard curves that more properly covered the 
physiological range of cytokine concentrations that were measured in this study (i.e. 
sigmoidal curve). Extending the lower end of the standard curve from S7 to S9 presumably 
permitted cytokines concentrations with MFI values extending below the S7 of 7 series curve 
to be more accurately quantified from the samples that would have been reported as 
undetectable.   
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Figure 2.4. IL-5 standard curves 
Red curve shows a typical 7 series suggested by the protocol and green curve shows a 9 series 
standard curve of three-fold dilutions. The bottom window shows a magnification of the upper 
window and it compares the low end of S9 and S7 series standard curves. The blue dotted line shows 
the background MFI for IL-5. 
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Figure 2.5. Possible standard curve response 
(a) Low response. (b) High response. (c) Sigmoidal response. Adapted from Bio-Plex ™ suspension 
array system (157). 
 High dose hook effect for plasma IL-13, MIP-1α and RANTES standard curves 2.9.
The standard curves of IL-13, MIP-1α, and RANTES from plate 6 plasma assay had a 
significantly reduced MFI at S1 and S2 when compared with the standard curves generated 
on the remaining 6 plates. The lower MFI was not corresponding with the expected cytokine 
concentrations at S1 and S2 which should be the highest in the 9 series standard curve. 
Although the cause of this was not investigated, the projection of these three cytokines could 
have demonstrated a phenomenon known as “high dose hook effect”, which is a form of 
antibody interference. The inferred problem is that the washing steps did not remove all the 
cytokines remaining in solution, i.e. that were not bound to the capture antibody/beads. These 
soluble cytokines would then compete for binding of the secondary antibody to the beads and 
reduce the MFI signal. The capture antibody is conjugated to the magnetic bead; all assay 
components not sandwiched to it are washed off, such as any soluble secondary antibody-
cytokine complexes (159-161). 
The hook’s effect for IL-13 and MIP-1α standard curves in plasma assay plate 6 occurred at 
MFI above the range of samples reading that were measured. The participants’ concentration 
for both IL-13 and MIP-1α could be estimated in the region below the hook effect (Figure 2.6 
a-b). The IL-13 and MIP-1α observations from these participants were included in the data 
analysis. On the other hand, the hook’s effect encountered with the RANTES standard curve 
was in the same MFI and concentration range as the participants’ samples’ concentration 
(Figure 2.6c). The concentration of RANTES within those samples could not be estimated 
with certainty using the standard curve generated in plate 6 assay. The RANTES standard 
curve that was chosen for extrapolating participants’ concentration was picked based on the 
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lower range of the substituting curve having similar MFI to the lower range of plate 6 
RANTES. Detailed standard curves of NPA assays and for the remaining plasma assays are 
shown in appendix H. 
 
Figure 2.6. Standard curves and hook effect for IL-13, MIP-1α and RANTES 
(a-b) The participants MFI for IL-13 and MIP-1α were below the hook effect region; therefore the 
concentration of these samples could be reliably predicted from the same standard curve. (c) The 
participants MFI for RANTES was in the same range as the hook effect region; therefore the 
concentration of these samples could not be reliably estimated from the same standard curve and the 
standard curve from plate 5 was used. 
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 Statistics for data analysis 2.10.
The statistical analyses of this study were performed using STATA version 13, (Stata Corp 
LP, USA) statistical software. Graphpad Prism 5 (GraphPad, San Diego) was used to draw 
box and whiskers diagrams. The Shapiro Wilk and Kurtosis test for normality were used to 
assess the normality distribution of all continuous variables.  
Demographic characteristics of the study participants were described using frequency Tables 
with percentage for categorical variables. Continuous variables were described using mean 
and standard deviations or median and interquartile range depending on the normality 
distribution of continuous variables. Median and interquartile range (25th and 75th 
percentiles) were used to describe the cytokine levels as they were not normally distributed. 
The 25
th
 and 75
th
 percentile is less affected by skewed data and it has been reported as a good 
measure of central tendency compared to 5
th
 and 95
th
 percentile (162). 
The Kruskal-Wallis test was initially used to evaluate demographic and cytokine variables for 
any existing difference between all three groups. For cytokine analysis, Bonferroni correction 
was made to the Kruskal-Wallis test and the critical p value (α=0.05) was divided by 15 to 
account for the number of cytokine comparisons. Following the Bonferroni adjustment, a 
p≤0.003 was considered to be the threshold for statistical significance. The Bonferroni 
correction was applied to decrease the chances of obtaining false-positive results. 
Demographic and cytokines variable that were not significant with the Kruskal-Wallis test 
were excluded from further analysis. 
 If group differences were significant for the demographic variables, then a Mann-Whitney 
test was used for one to one group comparison for continuous variables that were not 
normally distributed; alternatively a two-way student t-test was used for normally distributed 
demographic variable. Fisher’s Exact test was used for categorical variables. Demographic 
variables that were significantly different in one to one group comparison were considered as 
covariates. 
A covariate adjusted logistic regression was used to evaluate the relationship between each 
cytokine and the two levels of outcome i.e. control versus all RSV-LRTI or mild versus 
severe RSV-LRTI. The strength of association for all cytokines significant in severity was 
further quantified in a covariate adjusted multivariate logistic regression model. Variables 
with p<0.2 were included in a multivariate logistic model. Coefficients of variations were 
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reported as a measure of association between the RSV LRTI severity and the covariates. 
Hosmer Lemeshow test was used to investigate goodness of fit on the final model. 
MEDCALC software (MedCalc, USA) was used to generate receiver operation characteristic 
(ROC) curves, sensitivity and specificity report on the ability of significant demographic 
characteristic or cytokines to discriminate between a mild or severe RSV-LRTI. 
Correlation analyses using Spearman’s Correlation Coefficients were performed to compare 
the cytokines concentration between NPA and plasma samples.  
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Chapter 3: Results  
 The epidemiology of study participants 3.1.
Paired peripheral whole blood and NPA samples were collected from infants with PCR 
confirmed RSV-LRTI (n=202). The samples were also collected from control infants (n=31) 
without respiratory illness symptoms or pathogens detected (that we tested for) and were 
admitted to the hospital for elective surgery. RSV-LRTI cases were grouped into mild (n=89) 
and severe (n=113) based on their Respiratory Index of Severity in Children (RISC) score. 
Tables 3.1 and 3.2 depict the demographic characteristics and clinical symptoms at hospital 
admission of the participants included in the present study.  
3.1.1. Growth standards and demographics 
The control infants participants were younger than RSV-LRTI cases (median age 1.5 months, 
p<0.001). The majority of the participants were of black African origin. In the control group 
94% of the infants were males and this was significantly higher than in the severe (53%) and 
mild (49%) group (p<0.001) for both comparisons. 
Infants with severe RSV-associated LRTI were younger (median age 3.9 months) than those 
with mild RSV-LRTI (median age 4.5 months, p≤0.01). No difference was observed between 
the mild and severe RSV-LRTI cases in the proportions of full term vs. pre-term birth 
participants (p=0.1).  
Household characteristics were similar between the control group and, mild and severe RSV-
LRTI cases. Equal proportion of infants from the control group and RSV-LRTI cases were 
exposed to smoke in utero; 16% of infants with mild disease attended day care compared to 
the 6% severe group (p>0.05).  
The feeding habits were evaluated for all enrolled infants. A large portion of RSV-LRTI 
cases (mild=79% and severe=74 %) were never breastfed compared to the control group 
(39%, p<0.001); this analysis was adjusted for age at hospital admission because the control 
infants were younger than RSV-LRTI cases. Equal proportions of mild and severe RSV-
LRTI were never breastfed (79% vs. 74%). 
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Table 3.1 Demographic characteristics of RSV-LRTI cases and control infants 
Characteristics 
 
Control 
n = 31 
 
Mild 
n = 89 
 
Severe 
n =113 
Control 
vs. All 
RSV 
Mild 
vs. 
severe 
Growth standards           
Age, month, 
median (IQR)
b
 
1.5 (0.43 - 2.8) 4.5 (2.4 - 8.6) 3.9 (1.7 - 6.4) <0.001 0.01 
Admission weight, 
kg, median
b 
(IQR) 
5 (4 - 6) 6.7 (5.5 - 8.5) 5.6 (4.2 - 7) <0.001 <0.001 
Gender        
 
  
Female 2 (6) 45 (51) 60 (53) <0.001 0.86  
Male 29 (94) 44 (49) 53 (47) 
 
  
Gestation age            
Full term  31 (100) 61 (69) 68 (60)     
Pre term - 13 (14) 26 (23) <0.001 0.1 
Unknown - 15 (17) 19 (17)     
Ethnicity            
Black 28 (90) 86 (97) 107 (95) NS NS 
Coloured 3 (10) 3 (3) 6 (5)     
Underlying 
medical condition  
          
No 31 (100) 75 (84) 105 (93) NS   NS 
Yes - 1 (1) 1 (1)     
Unknown - 13 (15) 7 (6)     
Household background          
Smoke exposure 
during pregnancy  
          
No 29 (94) 83 (93) 108 (96) NS NS 
Yes 2 (6) 6 (7) 6 (4)     
Alcohol exposure 
during pregnancy  
          
No 31 (100) 89 (100) 108 (96) NS NS 
Yes   - 5 (4)     
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Smoke exposure 
from caregiver  
          
No 31 (100) 87 (98) 111 (98) NS NS 
Yes   2 (2) 2 (2)     
Day care 
attendance  
          
No 31 (100) 75 (84) 106 (94) NS NS 
Yes   14 (16) 7 (6)     
Feeding practices during the first 4 months of life 
Ever breastfed    19 (61) 19 (21) 29 (26) <0.001
*
 0.5
*
 
Never breastfed
 
 12 (39) 70 (79) 84 (74)     
Abbreviations: IQR, Interquartile range; kg, kilogram; Non-significance, NS. Data are presented as 
number (%) unless otherwise specified. A Kruskal-Wallis test was performed to evaluate differences 
within the three groups. A p≤0.05 was considered to be statistically significant. Not significant (NS) 
was assigned to all group comparisons for measures with Kruskal-Wallis p≥0.05; these data were not 
tested any further. If group differences were significant, then Fisher’s exact test was used for one to 
one group comparisons to test differences in the frequency of categorical variable. 
b
Mann-Whitney 
test was used for one to one group comparisons to test for equality of the characteristic’s median. 
*
Age at hospital admission adjusted logistic regression analysis. 
 Clinical symptoms presented by RSV-LRTI cases at hospital admission 3.2.
Infants with RISC score (150) <2 were categorised as mild RSV-LRTI cases and those with a 
score ≥2 as severe RSV-LRTI cases. Figure 3.1 depicts the RISC score distribution of RSV 
LRTI cases. Table 3.2 includes the clinical data used to score the disease severity among the 
cases. Pulse oximetry oxygen saturation measures were available for 108 severe RSV-LRTI 
cases and 72 mild RSV-LRTI cases, of who 31% and 1% had oxygen saturation ≤90%, 
respectively. For the participants with no oxygen saturation information available, points to 
calculate the RISC score were allocated based on whether they had received oxygen 
supplementation or not; 58% of infants with severe RSV-LRTI required oxygen 
supplementation compared to 7% with mild RSV-LRTI. 92% of the RSV-LRTI infants with a 
severe RSV-LRTI presented with hypoxia at hospital admission. The RISC criteria for HIV-
uninfected were applied to HIV-uninfected infants including those who were HIV-exposed 
but remained uninfected; similarly the HIV-infected RISC criteria were used to score the 
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RSV-LRTI severity of HIV-infected infants. The proportions of infants who were HIV-
infected or exposed were not different between all three study groups.  
The respiratory symptoms presented by the RSV-LRTI infants at hospital admission are also 
included in Table 3.2. RSV-LRTI infants more often (>93%) had a history of cough or 
presented with cough symptoms at examination. The symptoms included runny nose or 
coryza, nasal flaring and chest crepitation. Expiratory grunting was observed in 5 RSV-
infected infants and apnoea in 4; stridor was observed in 3 infants in the severe group. The 
vital signs recorded at hospital admission included heart rate, respiratory rate and 
temperature.  The median heart rate presented by mild (n=71) and severe (n=102) RSV-LRTI 
cases was 164 versus 157 beats per minute respectively. The median respiratory rate observed 
for mild RSV-LRTI (n=80) was 57 breaths per minute and 60 breaths per minute for severe 
RSV-LRTI cases (n=101). Both the mild (n=81) and severe (n=97) RSV-LRTI cases had a 
median body temperature of 36.8°C at hospital admission. 
Only 1 RSV-LRTI case was admitted to intensive care unit. Infants with severe RSV-LRTI 
had extended length of hospital stay compared to mild RSV-LRTI (3 days vs. 2 days, 
p<0.001). None of the participants died during hospitalisation. 
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Figure 3.1.Distribution of RISC score in RSV-LRTI infants 
The RISC score for HIV uninfected (exposed and unexposed) ranged from -2 to 6. The maximum 
RISC score for HIV infected infants was 7. 
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Table 3.2 Clinical symptoms presented by RSV-LRTI cases at hospital admission 
Clinical symptoms at hospital admission N (%) 
Mild Severe 
n = 89 n = 113 
RISC Score     
Oxygen saturation %, median (IQR) 96 (94 - 98) 97(90- 100) 
Observed frequency n = 72 n = 108 
Oxygen saturation ≤ 90 % 1 (1) 33 (31) 
Oxygen supplementation
 
     No 83 (93) 48 (42) 
                Yes 6 (7) 65 (58) 
Chest wall retraction    No 43 (48) 9 (8) 
 Yes 46 (52) 104 (92) 
Wheezing                     No 24 (27) 76 (67) 
Yes 65 (73) 37 (33) 
Feeding intolerance     No 78 (88) 86 (76) 
Yes 11 (12) 27 (24) 
WHO weight for age z (WAZ) score,  
- 0.2 ± 0.1 - 1.1 ± 0.2  
mean ± SE 
HIV Uninfected 84 (94) 101 (89) 
Unexposed 73 (82) 82 (73) 
Exposed 9 (10) 14 (12) 
Unknown exposure 2 (2) 5 (4) 
HIV Infected 5 (6) 12 (11) 
Respiratory system symptoms     
Cough history or at examination No 5 (6) 2 (1) 
                              Yes 83 (93) 108 (96) 
                           Unknown 1 (1) 3 (3) 
Post-tussive vomiting     No 1 (1) 1 (1) 
     Yes 11 (12) 18 (16) 
Unknown 77 (87) 94 (83) 
Runny nose/ coryza        No 58 (65) 76 (67) 
    Yes 30 (34) 36 (32) 
Unknown 1 (1) 1 (1) 
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Nasal flaring                   No 67 (75) 77 (68) 
    Yes 21 (24) 36 (32) 
Unknown 1 (1) - 
Apnoea                           No 87 (98) 111 (98) 
    Yes 1 (1) 2 (2) 
Unknown 1 (1) - 
Crepitation                     No 49 (55) 40 (35) 
   Yes 40 (45) 73 (65) 
Stridor                            No 0 (100) 110 (97) 
    Yes  - 3 (3) 
Expiratory grunting        No 88 (99) 109 (96) 
   Yes 1 (1) 4 (4) 
Vital signs at admission     
Heart rate (beats per minute), median (IQR) 164 (148 -174) 157 (147-172) 
Observed frequency n = 71 n = 102 
Respiratory rate (breaths per minute) median 
(IQR) 
57 (46 - 63) 60 (52 -68) 
Observed frequency n = 80 n = 101 
Temperature (°C), median (IQR) 36.8 (36.5 - 37.3) 36.8 (36.5 - 37.5) 
Observed frequency n = 81 n = 97 
Abbreviations: IQR, Interquartile range. Data are presented as number (%) unless otherwise specified.  
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 RSV Testing  3.3.
The nasopharyngeal swabs from RSV-LRTI cases and nasopharyngeal aspirate from controls 
were tested for RSV infection by PCR. The median cycle of quantification (Cq) was similar 
among the mild and severe RSV-LRTI (27.2 vs. 28.3, p=0.2) data not shown. Since Cq is a 
proxy for viral load this suggests that viral load did not influence the outcome of severity in 
this study. 
 Plasma cytokines 3.4.
Plasma concentrations for cytokines IL-1α, IL-1β, IL-5, IL-9, and IL-12p70 were below the 
limit of detection (LOD) across all study groups included (Table 3.3a). Plasma IL-8 was 
observed at levels above LOD, but these levels were not different between control infants and 
RSV-LRTI cases (Table 3.3a). Cytokine levels from Table 3.3a that were different between 
two or all three groups (p<0.003) were further studied to evaluate their association with 
RSV-LRTI and RSV-LRTI severity (Table 3.3b).  
3.4.1. Plasma cytokines: Control versus RSV-LRTI cases 
Table 3.3b includes the cytokine levels in the plasma for control versus RSV-LRTI. IFN-γ (3 
pg/ml vs. 5 pg/ml, p=0.02) and MIP-1α (12 pg/ml vs. 28 pg/ml, p=0.008) were reduced in 
RSV-LRTI cases compared to control infants. RSV-LRTI was associated with increased 
levels of plasma TNF-α when compared to control infants (0.7 pg/ml vs. <0.5 pg/ml, 
p=0.007). Anti-inflammatory cytokine IL-10 was elevated in the plasma of RSV-LRTI cases 
compared to control infants (1.0 pg/ml vs. <0.6 pg/ml, p=0.02). Plasma levels for IL-4, IL-6, 
and RANTES were not different between RSV-LRTI cases and controls. 
3.4.2. Plasma cytokines: Mild versus severe RSV-LRTI  
Median level of plasma IFN-γ was higher in severe RSV-LRTI (4 pg/ml) than mild RSV-
LRTI (3 pg/ml, p=0.055). Additionally, Table 3.3b shows that the plasma TNF-α, Th2 type, 
pyrogenic, chemokines and anti-inflammatory cytokines were not significantly different 
between mild and severe group.  
In general, the IFN-γ and MIP-1α plasma levels declined as a result of RSV-LRTI. Higher 
levels of plasma IFN-γ were associated with the outcome of severe RSV-LRTI. TNF-α was 
also elevated as a consequence of RSV-LRTI. RSV-LRTI induced a systemic immune 
regulation as indicated by elevated levels of plasma IL-10. 
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Table 3.3a Plasma cytokine concentrations (pg/ml) in control infants, mild and severe RSV-LRTI 
cases 
Cytokines LOD 
Control 
n = 31 
Mild 
 n= 89 
Severe 
n = 113 
All groups 
Th1 type  
IFN-γ 1 5 (3-5) 3 (2-4) 4 (3-5) <0.001 
IL-1α 8.9 0.2
*
 0.2
*
 0.2
*
 NS 
IL1-β 31.7 31.7
*
 31.7
*
 31.7
*
 NS 
IL-2p70 10 10.0
*
 10.0
*
 10.0
*
 NS 
TNF-α 0.5 0.5
*
 0.7 (0.5
*
-1) 0.7 (0.5
*
-1) <0.001 
Th2 type  
IL-4 3.2 3.2
*
 5 (3.2
*
-6) 3.2
*
 (3.2
*
-5) <0.001 
IL-5 0.2 31.8
*
 31.8
*
 (31.8
*
-0.3) 31.8
*
 NS  
IL-9 2 2.0
*
 2.0
*
 2.0
*
 NS 
IL-13 1.6 1.6
*
 1.6
*
 (1.6
*
-2) 1.6
*
 NS 
Pyrogenic     
IL-6 0.6 0.6
*
 0.6 (0.6
*
-2) 1.0 (0.6
*
-3) <0.001 
Chemokines 
IL-8 3.1 10.3 (3.1
*
-20.0) 4.9 (3.1
*
-11.2) 6.3 (3.1
*
-14) NS 
MCP-1 31.8 102 (69-230) 63 (41-139) 64 (3-126) NS 
MIP-1α 6.3 28 (26-37) 14 (10-22) 11.3 (7-20) <0.001 
RANTES 6.6 552 (509-591) 498 (328-940) 431 (348-536) 0.002 
Anti-inflammatory       
IL-10 0.6 0.6
*
 1.2 (0.7-3) 1.1 (0.6
*
-2) <0.001 
Abbreviations: not-significant, NS. Data are presented as median (25th - 75th percentile). Kruskal-
Wallis test was performed to evaluate median differences between study groups and a Bonferroni 
correction was applied; critical p value (α=0.05) was divided by the number of cytokines (i.e. 15) 
being compared in plasma samples. Following the Bonferroni adjustment, a p≤0.003 was considered 
to be the threshold for statistical significance. If the Kruskal-Wallis was not significant, the cytokine 
was excluded in further analysis. If group differences were significant, then a covariate adjusted 
logistic regression was used to evaluate association between cytokine and RSV-LRTI or RSV-LRTI 
severity. * Cytokine level below limit of detection (pg/ml) 
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Table 3.3b Plasma concentrations (pg/ml) of the cytokines that were different in control, mild and severe RSV-LRTI infants 
Cytokines LOD 
Control 
n = 31 
RSV LRTI 
n=202                                                                                                                                                                                                                                                                  
Mild 
n = 89 
Severe 
n = 113
Control vs. 
RSV 
LRTI
a
 
Mild vs. 
severe
b
 
Th1 type 
IFN-γ 1.0 5 (3-5) 3 (2-4) 3 (2-4) 4 (3-5) 0.02 0.055 
TNF-α 0.5 0.5
*
 0.7 (0.5
*
-1) 0.7 (0.5
*
-1) 0.6 (0.5
*
-1) 0.007 0.6 
Th2 type  
IL-4 3.2 3.2
*
 3.7 (3.2
*
-5) 5 (3.2
*
-6) 3.2
*
 (3.2
*
-5) 0.4 0.9 
Pyrogenic        
IL-6 0.6 0.6
*
 0.8 (0.6
*
-2) 0.6 (0.6
*
-2) 1.0 (0.6
*
-3) 0.1 0.8 
Chemokines          
MIP-1α 6.3 28 (26-37) 12 (8-21) 14 (10-22) 11.3 (7-20) 0.008 0.9 
RANTES 6.6 552 (509-591) 448 (338-583) 498 (328-940) 431 (348-536) 0.08 0.1 
Anti-inflammatory 
 
         
IL-10 0.6 0.6
*
 1.0 (0.6-2) 1.2 (0.7-3) 1.1 (0.6
*
-2) 0.02 0.9 
Notes: Data are presented as median (25th - 75th percentile). p≤0.05 was statistically significant.*Cytokines levels below the limit of detection. aCovariate 
adjusted (age at hospital admission, gender, gestation age, breast milk feeding) logistic regression for plasma cytokines associated with RSV-LRTI. 
b
Covariate adjusted (age at hospital admission) logistic regression for plasma cytokines associated with RSV-LRTI severity. 
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Figure 3.2. Plasma cytokines that were different in control vs. RSV-LRTI or mild and severe 
RSV-LRTI infants.  
(a)The IFN-γ and (c) MIP-1α plasma levels declined as a result of RSV-LRTI. (a) Higher levels of 
plasma IFN-γ were associated with the outcome of severe RSV-LRTI. (b) TNF-α levels were higher 
in RSV-LRTI compared to control. (d) RSV-LRTI induced systemic immune regulation as shown by 
higher levels of IL-10 in RSV-LRTI cases compared to control.  
 
 Nasopharyngeal aspirate cytokine 3.5.
Nasopharyngeal aspirate IL-1β, IL-9, and RANTES concentration were below LOD 
(Table 3.4a). IFN-γ, IL-1α, IL-12p70, and IL-4 were detected at levels above the LOD in 
RSV-LRTI cases but not in control infants. The levels of IL-13 were equal in both RSV-
LRTI cases and control infants. Cytokines levels from Table 3.4a that were different 
between two or all three groups (p<0.003) were further studied to evaluate their 
association with RSV-LRTI and RSV-LRTI severity (Table 3.4b). 
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3.5.1.  Nasopharyngeal aspirate: Control versus RSV-LRTI cases 
Th1 type cytokine TNF-α levels were higher in the NPA of RSV-LRTI cases than in control 
infants (8pg/ml vs. 1.4pg/ml, p=0.01). Pyrogenic cytokine IL-6 median levels were also 
higher in the NPA of RSV-LRTI cases than in control infants (43pg/ml vs. 3pg/ml, p=0.07).  
IL-8 (2682pg/ml vs. 184pg/ml, p=0.002), MCP-1 (287pg/ml vs. 66pg/ml, p<0.001) and MIP-
1α (27pg/ml vs. <6.7pg/ml, p=0.004) were elevated in RSV-LRTI cases compared to control 
infants. IL-8, MCP-1 and MIP-1α are all important chemokines that attract immune cells to 
the infection site.  Anti-inflammatory IL-10 median levels were also increased in RSV-LRTI 
cases than in control (3pg/ml vs. <0.8pg/ml, p=0.4).  
3.5.2. Nasopharyngeal aspirate: Mild versus severe RSV-LRTI 
Although the median levels were slightly higher in mild compared to severe RSV-LRTI 
(29pg/ml versus 27pg/ml, p=0.05), the spread of the interquartile range showed that in 
general severe RSV-LRTI cases (12pg/ml, 67pg/ml) had higher MIP-1α levels compared to 
mild RSV-LRTI (10pg/ml, 103pg/ml) respectively. In a multivariate logistic regression 
(Table 3.8), coefficient of variation for NPA MIP-1α was positive indicating that increased 
cytokine levels were associated with increased severity. This was also true for a univariate 
logistic regression (data not shown). Additionally, Figure 3.3d below shows that severe cases 
appear to have increased levels of MIP-1α than the mild cases. For this reason, the mean 
concentrations (88pg/ml vs. 50pg/ml) of MIP-1α for severe and mild RSV-LRTI are shown 
in the abstract and not medians. 
In general, the median levels of pro-inflammatory cytokines TNF-α, IL-6, IL-8, MCP-1, 
MIP-1α, were increased in RSV-LRTI cases compared to the control group. Increased levels 
of MIP-1α were associated with the outcome of severe RSV-LRTI. Taken together, this 
indicated that the immune response was targeted towards the respiratory tract. Median level 
of anti-inflammatory cytokine, IL-10 was also increased in RSV-LRTI cases. This strongly 
suggests that the pro-inflammatory immune response was regulated. 
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Table 3.4a Nasopharyngeal aspirate cytokine concentrations (pg/ml) in control infants, mild and 
severe RSV-LRTI cases 
Cytokines LOD 
Control 
n =31 
Mild 
n = 89 
Severe 
n = 113 
All 
groups 
Th1 type 
IFN-γ 1.1 1.1
*
 1.1
*
 (1.1
*
-2) 1.1
*
 (1.1
*
-2) NS 
IL-1α 7.8 7.8
*
 7.8
*
 (7.8
*
 - 9) 7.8
*
 NS 
IL1-β 17.3 17.3
*
 17.3
*
 17.3
*
 NS 
IL-12p70 15.7 15.7
*
 15.7
*
 15.7
*
 (15.7
*
-16) NS 
TNF-α 1 1.4 (1.0
*
-6) 7.4 (3-22) 8 (2-34) <0.001 
Th2 type      
IL-4 4.6 4.6
*
 (4.6
*
-8) 5.2 (4.6
*
-11)  4.6
*
 (4.6
*
-9) NS 
IL-5 0.6 0.6
*
 (0.6
*
-1) 0.6
*
 0.6
*
 NS 
IL-9 1.2 1.2
*
 1.2
*
 1.2
*
 NS 
IL-13 2.9 2.9
*
 (2.9
*
-4) 2.9
*
 (2.9
*
-4) 2.9
*
 (2.9
*
-4) NS 
Pyrogenic      
IL-6 0.7 3.1 (0.9-10.1) 50 (18-100) 40 (1-102) <0.001 
Chemokines       
IL-8 2.6 184 (91.0-778) 3437 (1551-7690) 2598 (1133-6072) <0.001 
MCP-1 35.1 66 (37-195) 307 (205-363) 274 (170-372) <0.001 
MIP-1α 6.7 6.7
*
 (6.7
*
-11) 29 (12-67) 27 (10-103) <0.001 
RANTES 5.3 5.3
*
 5.3
*
 5.3
*
 NS 
Anti-inflammatory         
IL-10 0.8 0.8 (0.8-3) 3.2 (1-8) 3 (1-7) 0.003 
Abbreviations: not-significant, NS. Data are presented as median (25th - 75th percentile). Kruskal-
Wallis test was performed to evaluate median differences between study groups and a Bonferroni 
correction was applied; critical p value (α=0.05) was divided by the number of cytokines (i.e. 15) 
being compared in plasma samples. Following the Bonferroni adjustment, a p≤0.003 was considered 
to be the threshold for statistical significance. If the Kruskal-Wallis was not significant, the cytokine 
was excluded in further analysis. If group differences were significant, then a covariate adjusted 
logistic regression was used to evaluate association between cytokine and RSV-LRTI or RSV-LRTI 
severity. * Cytokine level below limit of detection (pg/ml). 
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Table 3.4b Nasopharyngeal aspirate concentrations (pg/ml) of the cytokine that were different in control, mild and severe RSV-LRTI infants 
Cytokines LOD 
Control  
n = 31 
RSV LRTI  
n = 202 
Mild 
 n = 89 
Severe 
 n = 113 
Control vs. 
RSV LRTI
a
 
Mild vs. 
severe
b
 
Th1 type  
TNF-α 1.0 1.4 (1.0
*
-6) 8 (2-31) 7 (3-22) 8 (2-34) 0.01 0.3 
Pyrogenic 
IL-6 0.7 3 (0.9-10) 43 (14-99) 50 (18-100) 40 (1-102) 0.07 0.9 
Chemokines          
IL-8 2.6 184 (91-778) 2682 (1165-6072) 3437 (1551-7690) 2598 (1133-6072) 0.002 0.1 
MCP-1 35 66 (37-195) 287 (186-372) 307 (205-363) 274 (170-372) <0.001 0.8 
MIP-1α 6.7 6.7
*
 (6.7
*
-11) 27 (10-82) 29 (12-67) 27 (10-103) 0.004 0.05 
Anti-inflammatory  
IL-10 0.8
*
 0.8
*
 (0.8
*
-3) 3 (1-7) 2.5 (1-8) 3 (1-8) 0.4 0.6 
Notes: Data are presented as median (25th - 75th percentile). p<0.05 was statistically significant.
 *
Cytokines levels below the limit of detection. 
a
Covariate adjusted (age at hospital admission, gender, breast milk feeding) logistic regression for NPA cytokines associated with RSV-LRTI. 
b
Covariate adjusted (age at hospital admission) logistic regression for NPA cytokines associated with RSV-LRTI severity. * Cytokine level below 
limit of detection (pg/ml).    
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Figure 3.3.Nasopharyngeal aspirate cytokines that were different in control vs. RSV-LRTI or mild and severe RSV-LRTI infants. 
 (a)-(c) TNF-α, IL-8, and MCP-1 were elevated due to RSV-LTRI. (d) Severe RSV-LRTI cases had higher MIP-1α levels compared to mild RSV-LRTI.
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 Correlations of plasma and nasopharyngeal aspirate cytokine levels 3.6.
Spearman correlation analyses were used to investigate the relationship between cytokines 
concentration in plasma and nasopharyngeal aspirate (NPA) of mild and severe RSV-LRTI 
infants (Table 3.5). During RSV-LRTI episodes, increases in plasma IL-10 was associated 
with increased NPA IL-10 (r=0.25, p<0.001), MCP-1 (r=0.16, p=0.02) and IL-8 (r=0.15, 
p=0.03). Additionally, plasma IL-6 had a positive correlation with NPA TNF-α (r=0.19, 
p=0.01). There was an inverse relationship between plasma IFN-γ and NPA IL-8 (r=-0.17, 
p=0.01). Figure 3.4 shows significant correlation between plasma and NPA cytokines. 
The reason for observing a low strength of correlation with significant p value is that, this 
study had a large sample size to show small effect or association between cytokines. For 
some RSV-LRTI cases, the relationship between certain plasma and NPA cytokines obeyed a 
positive or negative correlation. This resulted in a significant p value. Since other RSV-LRTI 
cases were clustered around the fitted linear model for positive or negative correlation, this 
resulted in a weak strength of correlation. In this study, the results with (p<0.05) are  
meaningful; as they show that plasma and NPA cytokines are related to each other, and not 
that one cytokine in the plasma or NPA directly or indirectly caused the other and vice versa 
(163, 164).  
Table 3.5.Correlations between plasma and nasopharyngeal aspirate cytokine concentrations of mild 
and severe RSV-LRTI infants 
 
 
 
 
 
 
 
Notes: Correlation coefficients between cytokines in plasma and nasopharyngeal aspirates for RSV-
LRTI cases. Correlation coefficients shown in bold are significant (p<0.05). 
Cytokines (n=202) 
    Nasopharyngeal aspirate   
IL-10 IL-6 MIP-1α MCP-1 TNF-α IL-8 
  IL-10 0.25 0.10 0.08 0.16 0.07 0.15 
  IL-6 0.06 0.04 0.04 0.08 0.19 -0.03 
  RANTES 0.04 0.11 0.02 0.06 0.07 -0.14 
Plasma MIP-1α -0.04 -0.01 -0.01 -0.04 0.01 -0.08 
  IFN-γ 0.05 0.11 0.08 0.06 0.00 -0.17 
  TNF-α -0.03 0.00 -0.04 -0.02 -0.12 -0.35 
  IL-4 -0.54 -0.02 -0.05 -0.11 0.05 -0.07 
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Figure 3.4. Cytokines that are significantly correlated between plasma and nasopharyngeal 
aspirates. Correlations between: (a) plasma IL-10 and NPA IL-10, (b) plasma IL-10 and NPA MCP-
1, (c) plasma IL-10 and NPA IL-8, (d) plasma IL-6 and NPA TNF-α, (e) plasma IFN-γ and NPA IL-8. 
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 Discriminating severe from mild RSV disease 3.7.
The strength of association between cytokine concentrations and RSV-LRTI severity 
observed in Tables 3.3b and 3.4b was quantified with a multivariate logistic regression 
analysis (Table 3.6) adjusted for age at hospital admission. Cytokines with p<0.2 for 
comparison of mild versus severe RSV-LRTI were included. In a multivariate model, plasma 
IFN-γ (p=0.2) was associated with increased RSV-LRTI severity in concert with other 
cytokines. Nasopharyngeal aspirate MIP-1α was strongly associated with RSV-LRTI severity 
(p=0.05) with a coefficient of variation positive indicating that a higher MIP-1α level at 
hospital admission was associated with increased RSV-LRTI severity. Increased levels for 
plasma RANTES (p=0.06) and nasopharyngeal aspirate IL-8 (p=0.06) were associated with 
reduced RSV-LRTI severity.  
Table 3.6.Criteria associated with RSV-LRTI severity 
 Logistic regression analysis (n = 202) 
RSV-LRTI severity Coefficient of variation 95 % Confidence Interval p value 
Age at admission -0.05    -0.15-0.05 0.4 
Plasma IFN-γ 0.11 -0.07-0.28 0.2 
Plasma RANTES -0.0007   -0.001-0.00003 0.06 
NPA IL-8 -0.00003    -0.0001-8.08e
-07
 0.06 
NPA MIP-1α 0.004 0.00003-0.008 0.05 
Goodness-of-fit 0.4 
Hosmer-Lemeshow 0.2 
 
Plasma IFN-γ and RANTES, nasopharyngeal aspirate IL-8 and MIP-1α were analysed further 
with the receiver operating characteristics curves in order to determine the cut-off values for 
discriminating the two levels of RSV-LRTI severity (Table 3.7). Severe RSV-LRTI cases 
were characterised by the following cytokine concentrations; plasma IFN-γ >2.7pg/ml and   
RANTES ≤550pg/ml, nasopharyngeal aspirate IL-8 ≤3593pg/ml and MIP-1α >104pg/ml. The 
cytokines could not solely discriminate RSV-LRTI cases at a risk of developing severe RSV-
LRTI from those who are most like to have a mild RSV-LRTI. It is most likely that the 
combination of all the cytokines in the multivariate model contribute to severity rather than 
an individual cytokine. 
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Combination of markers had high sensitivity but the specificity remarkably declined. This 
suggests a relatively low reliability for using even the combined model to identify children at 
risk of severe LRTI upon hospital admission. Therefore, the results of this model should be 
interpreted with other clinical data when predicting RSV-LRTI severity at hospital admission.  
Table 3.7.Ability of markers to predict disease severity 
Marker 
Cut-off 
value 
(pg/ml) 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
AUC 
Plasma IFN-γ >2.7  74 50 34 85 0.62 
Plasma RANTES ≤550 78 40 60 64 0.55 
NPA IL-8 ≤3593 63 48 59 73 0.58 
NPA MIP-1 α >104 25 90 55 10 0.51 
Combination of Markers           
Plasma IFN-γ & RANTES  86 37 63 67 0.68 
Plasma IFN-γ & NPA IL-8  88 31 62 65 0.66 
Plasma IFN-γ & NPA MIP-1α  76 47 65 61 0.65 
Plasma RANTES & NPA IL-8  85 35 62 65 0.62 
Plasma RANTES & NPA MIP-1α  90 24 60 66 0.59 
NPA IL-8 & NPA MIP-1α  90 18 58 59 0.64 
Performance of all combined markers 
Plasma IFN-γ             
Plasma RANTES   76 47 65 61 0.69 
NPA IL-8             
NPA MIP-1 α             
Abbreviations: PPV (%), positive predictive value; NPV (%), negative predictive value; AUC, area under 
the curve. 
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Chapter 4: Discussion  
In this study we measured the levels of the most relevant cytokines described in the literature 
to be implicated in RSV-LRTI severity as potential markers for severe or mild RSV-LRTI in 
children less than 12 months of age. In this study we found that RSV infection was associated 
with increased expression of MIP-1α, MCP, IL-8, and TNF- α in nasopharyngeal aspirate 
(NPA) and, IL-10 and TNF- α in plasma. IFN-γ levels were lower in the plasma of mild 
RSV-LRTI than in severe RSV-LRTI cases. Furthermore severe RSV-LRTI was associated 
with increased levels of NPA MIP-1α. In line with RSV literature, we also found that infants 
with severe RSV-LRTI were in general younger at hospital admission and experienced 
breathing problems. 
 Severe disease is associated with breathing problems 4.1.
We observed that severe disease was associated with breathing difficulty and the need for 
oxygen supplementation during hospitalisation. This was expected since the RISC model uses 
these variables as part of its severity categorisation, in accordance with Tabarani et al (2013) 
and Diaz et al (2015). In addition, these studies found that IL-1β was also elevated in infants 
requiring oxygen supplementation. We were unable to detect IL-1β in any of the studied 
groups. This could have been a consequence of our assay having a high LOD for IL-1β or 
simply because the cytokine was not secreted. Also, it has been suggested that increased 
levels of MIP-1α, MCP-1, and TNF-α in respiratory secretions during RSV infection may be 
associated with the need for oxygen therapy (117, 165). Although in our study, these 
cytokines were elevated in NPA of RSV infected infants they were not associated with 
severity except for MIP-1α.  
RSV-infected infants (52% of mild and 92% severe) presented with chest retraction. The 
respiratory rate of infants with severe disease was also elevated at hospital admission 
compared to infants with mild disease. Taken together these signified that RSV infection 
caused breathing difficulty and supported the use for oxygen supplementation. It was noted 
that a high proportion of RSV infected infants presented with wheezing and this was 
consistent with many other studies (166-169). In our study wheezing was associated with 
reduction of severity and it was largely observed among infants with a mild disease, 
suggesting that wheezing may be associated with physiological protection during RSV 
infections. 
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Most RSV infected infants had a history of cough or were coughing during admission and 
also had chest crepitation. Cold-like symptoms such as runny nose and nasal flaring were also 
frequent in RSV infected infants; what could mislead clinicians to dismiss RSV cases as 
common cold illness. Infants with severe RSV-LTRI had an extended length of hospital stay; 
which according to McMillan et al (1988) might be associated with hypoxia (169). 
 Breast milk feeding protects against RSV LRTI-associated hospitalization 4.2.
There is overwhelming evidence from epidemiological studies demonstrating that breast milk 
feeding can be beneficial against respiratory pathogens (170, 171) and RSV-LRTI (172). In 
line with previous studies (173), we also observed that lack of breast milk feeding was 
associated with RSV hospitalization. Breast milk is a complex nutrition source that contains 
antimicrobial substances, immune regulators with capabilities to provide infants with passive 
protection and  influences the development of mucosal immunity (174). Many studies have 
measured various cytokines in human breast milk (175-178) that were otherwise found to be 
reduced in infants (179-181). The study by Wong and Orgra (1986) demonstrated that RSV 
replication was reduced in RSV challenged neonatal cotton rats that were foster nurtured with 
breast-milk containing RSV acquired antibodies (182). Both these observations suggest that 
breast milk compensate for the late development of infants immune system. Breast milk 
feeding may however remain a challenge for HIV-infected mothers. 
 PCR quantitation cycle as proxy of viral load in nasopharyngeal aspirate was not 4.3.
associated to RSV-LRTI severity  
Polymerase chain reaction Quantitation cycle (Cq) value can be used as a proxy for viral 
load. A high Cq value means that the RSV RNA was not detected or viral load levels were 
low, and a low Cq value signifies that the RSV RNA was abundant, indicating high viral 
load. In accordance with Brand et al (2013), our study supports the findings that Cq value 
cannot differentiate infants with severe LRTI from those who have mild LRTI (183). This 
was in contradiction with the findings of a Kenyan study which suggested that Cq values 
could be a useful tool to diagnose severe LRTI (184). We speculate that these authors found 
an association between Cq value and severity because their study was community based. 
During RSV infection children begin to shed the virus between days 6-8 following infection 
(185). At this stage the viral load is very high and may vary according to levels of RSV 
severity. Most frequently the child would still be at home, thus collecting samples at this 
stage may have biased the Kenyan study to detect an association between RSV-LRTI severity 
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and Cq value. In contrast, infants in hospital-based studies such as ours may have been 
hospitalized at variable times along the course of infection. If time during the course of 
infection independently affects viral load, the association between viral load and severity may 
be lost in hospital admission studies. The viral load begins to decline at day 9 post-infection 
as it is contained by the immune system (186). At this time the clinical symptoms may start 
and only then, the parent of the child is alarmed and concerned enough to consult the 
hospital. In our study, this was the time samples were collected and the viral load that could 
predict RSV-LRTI severity may have already decreased. Similarly Wright et al. (2002) 
observed that the viral load in intubated children was not higher than in children who had 
mild RSV-LRTI (185). Thus, at the time we collected NPA samples, the severity may have 
already been defined by the viral load that was present before hospital admission.  
 Cytokines associations with RSV-LRTI and severity  4.4.
The type of immune respond that is induced during an infection depends on the cytokines that 
are produced by host cells such as epithelial cells, Th1 and Th2 T-cells or tissue residing 
macrophages. In this study we observed no evidence for distinct Th1 and Th2 cytokines in 
mild and severe RSV-LRTI cases.  
4.4.1. Plasma cytokines and associations with RSV-LRTI  
The plasma of RSV-LRTI cases had reduced levels of IFN-γ compared to the control infants. 
This was in line with Aoyagi et al. (2002) who observed reduced production of IFN-γ by 
gamma delta (γδ) T-cells from RSV-LRTI cases (187). These authors also showed that low 
levels of IFN-γ were accompanied by increased proportion of IL-4 producing cells. In our 
study IL-4 was measured above the LOD in RSV-LRTI cases but this was not associated with 
RSV-LRTI. It is possible that the IL-4 detected in our RSV-LRTI cases was associated with 
young age and not solely of RSV-LRTI. Studies from Bendelja et al. (2000) and Bont et al. 
(1999) showed that IFN-γ levels were reduced in the plasma of RSV-LRTI cases that had 
oxygen saturation below 95 % measured on oximeter or required ventilation (42, 99). Our 
study findings were in line with those studies, as most of our RSV-LRTI cases had breathing 
difficulty, required oxygen supplementation in addition to reduced IFN-γ. It is also possible 
that IFN-γ levels may have declined due to the IL-10 which was produced as a consequence 
of RSV-LRTI.  
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RSV-LRTI cases, had median plasma TNF-α concentrations of 1.0pg/ml slightly above the 
LOD (0.5pg/ml) while TNF-α was below LOD in control infants. According to Mella et al. 
(2013), TNF-α plasma levels below 1000pg/ml during RSV-LRTI indicated the need for 
hospitalization (188). This was in line with our study as all the RSV-LRTI cases were 
hospitalized. Bendelja et al, (2010) suggested that the low levels of plasma TNF-α produced 
during RSV-LRTI was a consequence of reduced response by monocytes expressing TLR-8 
(189).   
In our study, infants with RSV-LRTI had low levels of plasma MIP-1α compared to control 
infants. This result was in line with Moreno-Solis et al (2014) where the concentration of 
plasma MIP-1α decreased during RSV-LRTI (190). MIP-1α is mainly produced by 
monocytic phagocytes (128, 191). The declining plasma levels observed during RSV-LRTI 
may be a consequence of MIP-1α producing cells migrating from the peripheral blood 
towards the respiratory tract (190), possibly also contributing to airway obstruction. If indeed 
MIP-1α producing cells migrated away from the peripheral blood during RSV-LRTI, then 
this would explains the inadequate production of TNF-α observed in the plasma.  
RSV-LRTI cases had elevated plasma levels of IL-10 compared to controls. These findings 
were consistent with the study by Brand et al. (2013) conducted in the Netherlands which 
measured IL-10 in plasma of RSV-LRTI cases (183), and observed that the median 
concentration IL-10 was not associated with RSV-LRTI severity. IL-10 is an important 
immunoregulator during viral infections which alleviates excessive production of IFN-γ and 
TNF-α (192), thus preventing the progression from mild to severe RSV-LRTI by reducing 
immunopathology mediated by IFN-γ (138). Monocytes have been reported to be the 
producer of plasma IL-10 during RSV infection (193). 
4.4.2. Plasma IFN-γ is associated with RSV-LRTI severity  
The plasma of infants with mild RSV-LRTI was characterised by low levels of IFN-γ 
compared to severe RSV-LRTI. In a whole blood culture and cytokine induction study, 
Bendelja et al. (2002) demonstrated that, the peripheral blood mononuclear cells (PBMC) 
from mild RSV-LRTI cases had increased expression of IL-4 and reduced IFN-γ (94). 
Similarly Chen et al. (2002) observed that the production of IL-4 was suppressed and that 
IFN-γ was upregulated in infants with severe RSV-LRTI (89). The results of these studies 
and ours are however in contradiction with the findings of Brandenburg et al. (2000). In a 
similar whole blood culture study, Brandenburg et al. observed that RSV-LRTI cases had 
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reduced levels of IL-4 and high levels of IFN-γ irrespective of disease severity, and 
concluded that Th1-type immune response was present in RSV-LRTI infants (194).  
We hypothesize that mild RSV-LRTI cases may have a more competent immune response to 
RSV compared to those with severe RSV-LRTI. Majority of the leukocytes from mild RSV-
LRTI cases could migrate to the respiratory tract and limit the spread and replication of RSV. 
As a consequence of this immunological “calling” the peripheral blood of mild RSV-LRTI 
cases may have reduced number of IFN-γ producing cells.  
4.4.3. Nasopharyngeal aspirates cytokines and associations with RSV-LRTI  
In our study the concentration of many cytokines and chemokines involved in innate 
immunity were elevated in NPAs from RSV-LRTI cases suggesting that the immune 
response was being targeted to the respiratory tract (123). The control infants had low levels 
of nasopharyngeal aspirate chemokines. The immune cells responding to the nasopharyngeal 
aspirate chemokines in these infants were possibly required to fight low level of infections 
introduced by breathing. The respiratory tract of RSV-LRTI cases was characterised by 
increased levels of IL-6, IL-8, IL-10, MCP-1, MIP-1α, and TNF-α compared to control 
infants. Both macrophages and epithelial cells secrete IL-8, MCP-1, and MIP-1α in response 
to RSV (128, 195).  
Tsutsumi et al. (1996) using nasal washes also detected that IL-6 and TNF-α were secreted 
during RSV infection (196). Our results were also in agreement with Diaz et al. (2013) who 
observed that TNF-α nasopharyngeal aspirate levels increased during RSV-LRTI (197). 
Production of these cytokines is attributed as an early warning to infection and initiates an 
inflammatory response. IL-6 together with TNF-α stimulates the hypothalamus and pituitary 
gland inducing fever (198). IL-6 is also known to activate lymphocytes and to promote the 
development of adaptive immune response (135). TNF-α induces endothelial cells lining the 
blood vessels to become permeable and allows leukocytes to migrate from the blood (199). In 
the presence of increased levels of NPA MIP-1α, MCP-1 and IL-8, the activated granulocytes 
migrate from the blood to the respiratory tract. Activated lymphocytes also respond to MIP-
1α and MCP-1and could migrate to the respiratory tract (126, 200).  
The study of McNamara et al. (2005) showed that in nonbronchoscopic bronchoalveolar 
lavage IL-8 was secreted in large quantity compared to other chemokines what is in 
agreement with our study where we observed that NPA IL-8 was present in higher 
78 
 
concentration compared to other chemokines. Neutrophils are attracted to the infection site by 
following the IL-8 gradient concentration (201).  
As expected a large portion of the pro-inflammatory response occurred within the respiratory 
tract, and there was evidence of immune regulation. IL-10 triggered the immune regulation 
needed to reduce antigen presentation and secretion of other pro inflammatory mediators in 
order to reduce pathology caused by the immune system (138, 202). 
IFN-γ which was found to be associated with RSV-LRTI severity in the plasma and 
nasopharyngeal levels between control infants and RSV-LRTI cases were comparable. In the 
respiratory tract were viral particles are abundant; the RSV non-structural proteins (N1 and 
N2) may have been successful at antagonising the interferon signals by upregulating the 
expression of suppressor of cytokines signalling (SOCS). This could have consequently 
prevented IFN-γ associated antiviral activities to take place at the site of infection (25, 203). 
4.4.4. Nasopharyngeal aspirates MIP-1α is associated with RSV-LRTI severity 
The elevated NPA cytokines observed in our study is in line with the results of Bonville et al. 
(1999) who observed that MIP-1α was secreted into nasal washes during on-going RSV-
LRTI. High levels of MIP-1α were found to be a signature of RSV-LRTI (compared with 
adenovirus, herpes simplex virus-1, cytomegalovirus and rhinovirus infections) (123).  
In our study, MIP-1α was also associated with RSV-LRTI severity. MIP-1α is produced by 
tissue residing macrophages, lymphocytes and dendritic cells (204). MIP-1α attracts T 
lymphocytes, basophils and neutrophils to the infection site, and activates mast cells to 
degranulate (126). In the presence of MCP-1 as observed in this study, basophils will be 
activated to release histamine (126). Higher levels of MIP-1α were measured from the 
nasopharyngeal aspirate of severe RSV-LRTI cases than mild RSV-LRTI cases. In this study, 
the hallmark of MIP-1α in RSV-LRTI severity is that it acts in concert (with other 
chemokines) as a potent chemo attractant for different type of granulocytes and induces their 
effector functions. When an antibody receptors (Fc receptors) on the surface of cells (205), 
such as neutrophils, eosinophils, and natural killer cells make contact with viral particles 
opsonised by immunoglobulin (Ig) G or IgA (206),  reactive oxygen species  and anti-
microbial proteins (207) are released.  These may limit RSV from replicating and spreading 
to other areas (208). This may mediate immunopathology and exacerbate respiratory tissue 
damage causing severe RSV-LRTI.  
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 Correlation between plasma and nasopharyngeal aspirates cytokine levels 4.5.
We detected positive correlations for plasma IL-10 and NPA IL-10, IL-8, and MCP-1. The 
strength of correlation observed between the two compartments for these cytokines was 
modest but significant. Additionally, direct correlation was also observed for plasma IL-6 
with NPA TNF-α. Both plasma and NPA TNF-α were directly correlated to each other. 
Moreno-Solís et al. (2015) studied the correlation between cytokine levels in plasma and 
nasal washes (209). In contrast to our study, these authors observed a positive correlation 
between plasma and nasal wash MIP-1α. In the same study, plasma IL-8 increased with nasal 
wash levels.  
An inverse correlation was noted between plasma IFN-γ and NPA IL-8. This strengthens the 
hypothesis that during RSV infection the cells that produce plasma IFN-γ migrate out of the 
blood in response to the increased chemokine concentration within the respiratory tract. As a 
consequence, the plasma of RSV infected children had lower levels of IFN-γ compared to the 
controls. These results may suggest that the plasma and respiratory tract constitute 
independent compartments with regard to immune response and the two compartments are 
interconnected by chemokines. The respiratory chemokines might be the key mediators that 
influence the migration of cells from the blood towards the RSV infected compartment (190).  
 Cytokines below limit of detection compared with previous studies 4.6.
We were unable to detect plasma IL-1α, IL-1β, IL-9, IL-12p70, and NPA IL-1β, IL-9, and 
RANTES yet previous studies were able to measure them. Some cytokines were observed in 
this study at high or low magnitude compared to previous studies investigating RSV severity. 
This section discusses and compares to previous studies, the cytokines that were not detected 
in this study and yet have been described to be key to RSV immune response. 
4.6.1. Plasma cytokines not detected 
We did not observe plasma IL-1β. These results were consistent with the study by Brand et 
al. (2016) who studied cytokine responses in plasma and NPA of infant with RSV infection 
from the Netherlands and observed no IL-1β in plasma (Table 4.1) (183). These conflicted 
with Bermejo-Martin et al (2007) and colleagues who studied cytokine responses to RSV 
infection Spanish infants and detected IL-1β (median, 17.5pg/ml) in the plasma of RSV 
infants (210). If IL-1β was secreted into the plasma of our study participants at similar levels 
to those observed in Spanish infants, we were unlikely to have detected this range of 
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concentration since this value is below our LOD (31.7pg/ml). The study by Brand et al 
(2016), which had IL-1β LOD of 11.2pg/ml, should have been able to measure IL-1β at the 
levels reported in the Spanish study but it was not reported in Brand et al. (2016) study.  
IL-12p70 was not detected in our study nor a Dutch study (10.0pg/ml vs 0.6pg/ml LOD 
respectively) (183). Bermejo-Martin et al. (2007) study reported much higher levels of IL-
12p70,  median concentration of 28.9pg/ml. Brand et al. (2016) and our study was capable of 
measuring similar levels to the ones observed in the Bermejo-Martin et al. (2007) study if 
secreted at all. 
Our plasma results agree better with those of Brand et al. (2016) than with Bermejo-Martin et 
al. (2007); the latter which also used a Luminex based assay to measure cytokines similarly 
to our study. Other likely explanations for the observed difference could be that, during RSV 
infection cytokines are secreted differently in infants based on population variation. We also 
cannot rule out that unstable cytokines could have been too labile once they are collected into 
tubes and samples are handled.  Nonetheless, a review of the literature did not uncover 
unequivocal evidence that such degradation could explain our inability to detect IL-1β or IL-
12p70.  
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Table 4.1.Plasma cytokine below LOD compared to previous studies 
  
Cytokines 
 
 
Soweto 
study 
Previous studies 
LOD 
(pg/ml) 
Observed median 
concentration in RSV cases 
(pg/ml) 
Technique used Measure of Severity  Study country Reference 
IL-1β 31.7 
17.5 Luminex RSV versus control 
Spain, 
(210) Bermejo-Martin 
et al. (2007) 
    Undetected; LOD =11.2 Flow cytometer 
(Functionally similar method 
to Luminex) 
No supportive 
intervention=mild Netherlands 
(183) 
 
      
Oxygen need 
=moderate 
Brand et al. 
(2013) 
      Ventilation = severe   
IL-12p70 1 
28.9 Luminex RSV versus control 
Spain, 
(210) Bermejo-Martin 
et al. (2007) 
    
Undetected; LOD =0.6 
Flow cytometer 
(Functionally similar method 
to Luminex) 
No supportive 
intervention= mild Netherlands 
(183) 
 
    
Oxygen need = 
moderate 
Brand et al. 
(2013) 
    Ventilation = severe   
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4.6.2. Nasopharyngeal aspirate cytokines not detected 
IL-1β, IL-9, and RANTES were also below the limit of detection (LOD) in nasopharyngeal 
aspirates from RSV-LRTI infants. We specifically analysed IFN-γ because it has been 
highlighted as important for RSV immune responses (119). Kim et al. (2012) from South 
Korea, detected high levels of IFN-γ (median 4.4pg/ml) in nasal washes of RSV infected 
infants compared to control (below LOD) and associated this with eosinophilia inflammation 
(119). The opposite was observed in our study as the median IFN-γ level was equivalent to 
the LOD (1.1pg/ml). Additionally our results were similar to Brand et al. (2016) who also did 
not detect IFN-γ (LOD =1.2pg/ml) within the nasal wash of RSV infants. 
The median NPA levels of IL-1β observed from Bermejo-Martin et al. (2007), Brand et al. 
(2016) and 2 USA studies, Christiaansen et al. (2016) and Tabarani et al. (2013), all varied in 
magnitude as shown in Table 4.2. Both Bermejo-Martin et al. (2007) and Christiaansen et al. 
(2016) measured cytokines from RSV and control infants using Luminex technique. The 
median IL-1β levels reported in RSV cases varied widely: 15.6pg/ml to 468pg/ml. Brand et 
al. (2016) and Tabarani et al. (2013) studies used different techniques to measure cytokines; 
nonetheless both these studies showed that the levels of IL-1β increased with severity. 
Intriguingly, the most severe group from these two studies were infants admitted to ICU. 
Even though the severe groups were similar, IL-1β in infants from Brand et al. (2016) study 
was almost 4 times higher (1093pg/ml) than in infants (300pg/ml) from Tabarani et al. (2013) 
study. The different techniques used to measure cytokines, does not appear to be decisive in 
influencing the cytokine levels observed. If techniques had any influence, surely the levels 
observed from Bermejo-Martin et al. (2007) study (468pg/ml) which used Luminex would 
have differed greatly with the mild group from the Brand et al. (2016) study (552pg/ml) 
which used flow cytometer. An alternative explanation is that the affinity of the antibodies 
used in the detection kits for IL-1β could have varied from one study to the next.  
These previous studies have shown that IL-1β was secreted at various levels among different 
population and that the magnitude was not consistent with various measures of severity. 
Three studies reported concentrations in RSV cases above our calculated LOD. If IL-1β was 
secreted into the nasopharyngeal aspirate of our study infants, we would have had the ability 
to detect it since the LOD (17.3pg/ml) was lower compared to the measured medians levels 
of the 3 previous studies. The same would have been true for RANTES which was also not 
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detected in the nasopharyngeal aspirates from this study regardless of low LOD (5.3pg/ml) 
compared to median levels observed by 3 previous studies.  
Additionally, IL-9 was not detected in the nasopharyngeal aspirates from our study. IL-9 was 
differently expressed in two studies from UK (McNamara et al. (2014) and Semple et al. 
(2007)) both using ELISA. The McNamara et al. (2014) study showed that IL-9 levels 
declined with increasing severity, while the study by Semple et al. (2007) implicated high 
levels of IL-9 with severity. McNamara et al. (2014) however included pre-term infants as 
severe group and this could have influenced the different IL-9 levels observed among the 2 
studies, since prematurity is a well-known risk factor for severe RSV. Furthermore, our study 
included infants who had not been ventilated similarly to the non-severe group of McNamara 
et al. (2014) study. If IL-9 was secreted into the nasopharyngeal aspirate, we could have 
measured this cytokine because the LOD (1.2pg/ml) from our study was lower than the 
median level (1.9pg/ml) detected in the non-severe non-ventilated full term infants from 
McNamara et al. (2014) study.  
The studies published to date reported a very wide range of median concentrations for IL-1β, 
IL-9, and RANTES in NPA. Although it may be possible that cytokines are secreted 
differently among various ethnicities during RSV infection, some of the variation reported 
was within one country (IL-9 concentrations differing by about 50-100 fold in the two UK 
studies). The median concentrations reported were above our LOD in 3 of 4 studies for IL-1β, 
3 of 3 studies for RANTES and 1 of 2 studies for IL-9, suggesting that cytokines’ degradation 
in the sample during processing could be possible, particularly for RANTES, although there 
is no direct evidence to support this. It also remains possible that ethnic difference could play 
a role in the differences observed when comparing our South African data to the 
European/USA data in the literature summarised here. According to Hoffmann et al. (2002), 
high and low levels of cytokine production are greatly influenced by polymorphisms within 
the regulatory region of the cytokine genes (211, 212), and IL-1 gene cluster is a well know 
cytokine whose secretion is greatly influenced by ethnicity (212). Secretion of different 
cytokines levels have been measured in two different ethnic groups (from same geographical 
area) infected with Dengue virus (213). It is likely that the same is true for RSV infection. 
Polymorphisms of various cytokines have also been implicated in cytokine production levels 
including RSV severity (214-216).  
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Table 4.2.Nasopharyngeal aspirate cytokines not detected compared to previous studies 
Cytokine 
Soweto 
study 
Previous studies 
LOD 
(pg/ml) 
Observed median 
concentration in 
RSV cases (pg/ml) 
Measure of Severity Technique used Study country Reference 
IL-1β 17.3 
468 RSV versus control Luminex 
Spain, Bermejo-
Martin et al. (2007) 
(210) 
15.6 RSV versus control Luminex 
USA, Christiaansen et 
al. (2016) 
(217) 
552 No supportive intervention= mild 
Flow cytometer 
(Functionally 
similar method to 
Luminex) 
Netherlands, Brand et 
al. (2013) 
(183) 
1670 Oxygen need = moderate 
1093 Ventilation = severe 
126 Non-Hospitalised Luminex 
USA, Tabarani et al. 
(2013) 
(117) 
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149 Hospitalised not in ICU 
300 Admission to ICU 
RANTES 5.3 
78 RSV versus control ELISA 
USA,  Sheeran et al. 
(1999) 
(218) 
23.51 RSV versus control Luminex  
USA,  Christiaansen 
et al. (2016) 
(217) 
116 No supportive intervention= mild Flow cytometer 
(Functionally 
similar method to 
Luminex) 
Netherland, Brand et 
a.l (2013) 
(183) 
74 Oxygen need = moderate 
48 Ventilation = severe 
IL-9 1.2 
1.9 
Non-severe = Full term non-
ventilated 
ELISA 
UK,McNamara et al. 
(2004) 
(219) 
0.4 Severe = Preterm ventilated 
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112 No oxygen =mild 
ELISA 
UK, Semple et al. 
(2007) 
(220) 
210 Oxygen = moderate 
113 Ventilation = severe 
IFN-γ 1.1 
4.4 RSV vs. control Luminex 
South Korea, Kim et 
al. (2012) 
(119) 
LOD =1.2 
No supportive intervention= mild Flow cytometer 
(Functionally 
similar method to 
Luminex) 
Brand et al. (2013) (183) 
Oxygen need = moderate 
Ventilation = severe 
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 Soweto study: what did we learn? 4.7.
There are many studies around the world which have investigated association of cytokines 
with disease severity during RSV infection. Here we have glanced at few important studies 
from various countries; all these studies are in agreement that the levels of NPA cytokines 
and chemokines involved in the innate immunity increased during RSV infection regardless 
of the cytokine detection kit used. Additionally, the immune response observed in plasma 
varied greatly. The similarities observed in the expression of IL-6, IL-8, IL-10, MCP-1, MIP-
1α, and TNF-α in the respiratory tract may signify that there is a common pathway in which 
RSV or infected epithelial cells induce an immunological response. The most striking 
conclusion of this exercise comparing different studies is how different the studies’ results 
are from each other, even when comparing ethnically similar populations. This raises the 
possibility that technical differences may play a role; including affinities of antibodies used in 
detection kits, veracity of cytokine standard preparations and other factors associated with the 
details of how each set of experiment may have been performed. 
 Conclusion and future perspectives 4.8.
Severity of RSV-LRTI was associated with elevated plasma IFN-γ and nasopharyngeal 
aspirate (NPA) MIP-1α concentrations. There was an indirect correlation observed between 
plasma IFN-γ and nasopharyngeal aspirate IL-8. Supported by the observed correlation, the 
blood of mild RSV-LRTI cases may have had reduced number of IFN-γ producing cells. This 
suggested that in these cases, the immune response was directed towards the respiratory tract 
as a consequence of elevated NPA cytokine levels. This could have reduced progression to 
severe disease. This response may be impaired in more severe cases of RSV-LRTI; high 
levels of plasma IFN-γ may suggest that the cells remained in the blood. Since IFN-γ was not 
detected in the nasopharyngeal aspirate; future studies should not only study cytokine 
responses in plasma or nasopharyngeal aspirates but also study the immune cells in order to 
understand the complete immune response during RSV-LRTI. Additionally, the stability of 
nasopharyngeal aspirate cytokines collected into universal transport media should be 
investigated as we only adjusted for the dilution factor introduced during NPA collection. We 
observed no evidence of canonical Th1 or Th2 type cytokine responses. The concentrations 
of plasma IFN-γ and nasopharyngeal aspirate MIP-1α, which were associated with RSV-
LRTI severity, could not independently predict RSV-LRTI cases at risk of severe RSV-
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associated LRTI. We suggest that the results of this study should be interpreted together with 
clinical data when clinicians triage for level of care during RSV-LRTI.  
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Appendix A: Ethics certificate 
 
Figure 1.Copy of the ethics clearance certificate received from the HREC. 
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Appendix B: Turnitin Report 
 
Figure 2.The Turnitin report showing originality of the dissertation and study contents.  
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Appendix C: Respiratory Index of Severity in Children (RISC) Score 
 
The RISC score was used to group RSV infected infants into mild or severe disease. HIV 
positive and negative infants were scored accordingly as shown below. RISC score was 
obtained from Reed et al. (2012) (150).  
HIV non-infected children 
Severity of respiratory signs on physical exam:  
1. Oxygen supplementation?     Yes/No:    3 points 
2. Does the child have chest indrawing?   Yes/No Indrawing:    2 points 
3. Does the child have wheezing?    Yes/No Wheezing:    -2 points 
4. Has the child been refusing feedings?   Yes/No Refusal to feed:  1 point 
Growth standards: 
5. Weight for age ≤ 3?    Yes/No     2 points 
6. Age ≤ 90 days?      Yes/ No     1 point 
Total points: _______ 
(Maximum: 6) 
HIV infected children 
Severity of respiratory signs on physical exam:  
1. Oxygen supplementation?     Yes/No:    2 points 
2. Does the child have chest indrawing?   Yes/No indrawing:    1 point 
3. Does the child have wheezing?    Yes/No Wheezing:   -1 points 
4. Has the child been refusing feedings?   Yes/No Refusal to feed:   1 point 
Growth standards: 
5. Age         0–2 months:    2 points 
 3–12 months:   1 points 
 12 months:    0 points 
6. HIV Clinical Classification     C:    2 points 
A/B:    1 point 
None:    0 points 
Total points: _______ 
(Maximum: 7) 
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Appendix D: Reagent and sample preparation for assays 
Wash solution preparation 
A wash solution 10X concentrate that had formed a precipitate was dissolved by floating the 
wash solution 10X concentrate bottle in a 37 °C water bath until the precipitate had 
dissolved. 10X wash solution concentrate (15ml) were added to 285ml of distilled, 
autoclaved, filtered water.  
Preparing 1 X antibody beads 
The 10 X antibody bead concentrate was vortexed for approximately 1 minute prior to use. 
This action deviated from the protocol which was suggesting 30 seconds vortex plus 30 
seconds of sonication. The frequency of sonication was not provided by the manufacturer and 
we optioned to vortex longer. 2.5µl of the 10 X antibody bead concentrate was diluted in 
25µl of working wash solution to obtain a 1:11 dilution factor. This provided excess volume 
to make up loss of volume due to pipetting errors that may have accrued during bead transfer 
to the plate. Each assay well required 25µl of the diluted 1 X antibody bead. During the assay 
Table 1 below was used to prepare the scaled volume of 1X antibody bead solution from the 
10 X antibody bead. Both the stock and working solution were always protected from light. 
The beads were cross linked to fluorophore which lose fluorescence intensity when exposed 
to light; loosing fluorescence intensity could result in low levels of cytokines being falsely 
reported.  
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Table 1.Preparing volumes of 1X antibody beads working solution  
Number of wells to use on 
the plate 
Volume of 10 X antibody bead 
concentrate (µl) 
Volume of working wash 
solution (ml) 
24 60 0.6 
32 80 0.8 
40 100 1.0 
48 120 1.2 
56 140 1.4 
64 160 1.6 
72 180 1.8 
80 200 2.0 
88 220 2.2 
96 240 2.4 
The Table was adapted from Human cytokine 10-plex panel user manual page 10 (221). 
Standard curve preparation 
The lyophilised cytokine standards (S) were reconstituted within 1 hour of performing the 
assay. To reconstitute the cytokine standards, 0.334ml of assay diluent was added to each of 
the three cytokine standard vials when preparing standards for plasma samples assay.  
When preparing standards for NPA samples assay, 0.334ml constituting 50% assay diluent 
50% UTM mixture was added to each standard vial. This facilitated the standard matrix to 
match the NPA cytokines matrix collected into UTM and will be subjected to equal 
background fluorescence scatter. Plasma and NPA standards were prepared and assayed on 
separate plates with appropriately diluted standards. 
 The vial stopper was replaced and allowed to stand for 10 minutes undisturbed. Thereafter 
the vials were gently swirled and gently inverted 3 times to facilitate complete reconstitution. 
The standard vials were further allowed to stand at room temperature for another 5 minutes. 
The cytokine concentration of reconstituted standards from the kit insert is shown below in 
Table 2. At the end of incubation period, 0.333ml of standard was pipetted from each of the 
three standard vials into 1 sterile tube and created a multiplex cytokine standard with a total 
volume of approximately 1ml. This was labelled as standard (S) 1 and had a starting 3-fold 
dilution factor. This multiplex S1 cytokine standard cocktail included 15 cytokines this study 
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was investigating. S1 was the highest concentrated standard of the 3-fold 9 serial dilutions 
that was performed. The starting cytokine concentration of S1 following mixing of the three 
vials are also shown below in Table 2.  Figure 2b below show the preparation of the 7 and 9 
series standard curve. 
Table 2.Cytokine concentration of reconstituted standards   
Vial number & Cytokine 
name 
Reconstituted standard S1  concentration 
 Lot Number concentration (pg/ml)  (pg/ml) 
1- Lot number: A18815 IL-1α 6000 2000 
2- Lot number:1470602 MCP-1 27600 9200 
  MIP-1α 18250 6083.33 
  RANTES 19300 6433.33 
3- Lot number: 1654899 IFN-γ 3850 1283.33 
  IL-1β 7800 2600 
  IL-4 67000 22333.33 
  IL-5 6800 2266.67 
  IL-6 6850 2283.33 
  IL-8 1950 650 
  IL-9 2850 950 
  IL-10 28650 9550 
  IL-12(p70) 8650 2883.33 
  IL-13 8950 2983.33 
  TNF-α 11250 3750 
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Figure 2a.Preparation of cytokine standard curve for the first four plates.  
This Figure was adapted from the protocol insert provided with the kit. The Figure is also present in the Human cytokine 10-plex panel user manual page 9 
(221). 
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Figure 2b.Cytokine standard preparations used from the fourth plasma plate assay and the entire NPA plate assays.  
This Figure was adapted from the Figure provided with the protocol. The Figure is also present in the Human cytokine 10-plex panel user manual page 9 
(221). 
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Sample preparation for immunoassay 
Previously prepared plasma or NPA supernatant required for one assay analysis were 
removed from the -80 ˚C ultra-low freezers and allowed to thaw on ice. The samples were 
gently mixed by hand to avoid foaming. The plasma samples were diluted 1:1 (50µl of 
plasma and 50µl of assay diluent provided with the kit) relative to the standards, and the NPA 
samples were diluted 1,4ml:1ml (70µl of NPA and 50µl of assay diluent). All samples were 
kept at room temperature until loaded onto the plate. No test sample or cytokine standards 
were added to the wells designated for the blank samples. 
Plate layout 
The diagram below shows the plate layout that was used during the assay.  
 
Figure 3.Plate layout showing the position of blank (B), standards (S), and samples (X). Position X38 
was allocated to spiked control sample.  
Preparing 1 X Biotinylated Antibody 
The biotinylated antibody was provided with the kit as a 10 X concentrate. 10 X biotinylated 
antibodies (1ml) was diluted in 10ml of biotin diluent to obtain a 1 X working solution with 
1:11 dilution factor which covered for extra pipetting error.  Table 3 and equation 2 below 
were used to prepare the required volume of 1X biotinylated antibody according to the 
number of assay wells to be used during the assay; each well required 100µl of the 1X 
biotinylated antibodies. 
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Table 3.Preparing 1 X biotinylated antibody working solutions. 
Number of wells to 
be used on the plate 
Volume of 10X biotinylated 
antibody (µl) 
Volume of working 
wash solution (ml) 
24 240 2.4 
32 320 3.2 
40 400 4.0 
48 480 4.8 
56 560 5.6 
64 640 6.4 
72 720 7.2 
80 800 8.0 
88 880 8.8 
96 960 9.6 
The Table was adapted from Human cytokine 10-plex panel user manual page 13 (221). 
Streptavidin-PE preparation 
The streptavidin-PE was supplied as a 10 X concentrate and had to be diluted into a working 
solution before use. This reagent was prepared 15 minutes before the end of cytokine 
detection incubation period and was continuously protected from light. 10 X streptavidin-PE 
(10µl) was diluted in 100µl of streptavidin-PE diluent to obtain a 1X working solution. The 
dilution factor was 1:11 to allow for extra pipetting volumes. Each well required 100µl of the 
1 X streptavidin-PE, Table 4 below was used to prepare the 1 X streptavidin-PE according to 
the number of wells to be used during the assay. 
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Table 4.Preparing streptavidin-PE working solution 
Number of wells to 
be used on the plate 
Volume of 10X streptavidin-PE 
(µl) 
Volume of working wash 
solution (ml) 
24 240 2.4 
32 320 3.2 
40 400 4.0 
48 480 4.8 
56 560 5.6 
64 640 6.4 
72 720 7.2 
80 800 8.0 
88 880 8.8 
96 960 9.6 
This Table was adapted from Human cytokine 10-plex panel user manual page 15 (221). 
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Appendix E: Using handheld magnetic washer 
The 96-well flat bottom plate containing assay beads was placed onto the handheld magnetic 
washer, and safely secured with clips (step 1). The plate was undisturbed for 1 minute to 
allow the beads settle to the bottom of the plate. The magnetic washer and plate unit were 
held securely together and turned upside down to decant plate fluids (step 2), followed by 
gently blotting the plate on dry paper towel (step 3). Blotting the plate removed excess liquid 
which could cause cross contamination of assay wells. The magnetic washer and plate unit 
was gently turned to face up and the plate was removed from the handheld magnetic washer 
before adding a wash solution or any other reagent into assay wells (step 4) (222). These 
steps are repeated to wash the plate twice. 
 
Step 1     Step 2 
 
Step 3      Step 4 
Figure 4.Bio-Rad. "Bio-Plex® Handheld Magnetic Washer". Retrieved 2016/09/23, 2016, from 
http://www.bio-rad.com/webroot/web/pdf/lsr/literature/10023087.pdf 
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Appendix F: Luminex® 200™ instrument setup 
The Luminex® 200™ daily maintenance and calibration was done during the first 45 minutes 
of cytokine detection incubation period before each assay could be acquired. The machine 
and computer components were turned-on and the BioPlex Manager 5.0 software was 
launched. The instrument lasers were warmed up prior to instrument calibration and the user 
was notified by the system at the end of laser warming session. This was followed by a start-
up session which included the priming of the instrument to remove any air bubbles that could 
be trapped within the fluidics system, and flushing the fluidics with 70% ethanol and distilled 
water.  
The Luminex® 200™ was calibrated with CAL1 and CAL2 (BioRad, USA) control beads on 
MCV plate IV (BioRad, USA) following the instructions elicited by the software. CAL1 
calibrates the classification of magnetic beads while CAL2 calibrates the reporter 
fluorescence. The instrument was kept in an air-cooled room of approximately 24 °C because 
the calibration standards are maintained at room temperature changes of not more or less than 
2 °C; severe temperature deviation could require the calibration to be redone. One assay plate 
was acquired daily and the instrument was primed, flushed with alcohol, bleach and distilled 
water before instrument and computer shutdown. 
A once-off Luminex® plate protocol was prepared and saved for the assay acquisition using 
the reference card provided in the kit. The details of Table 5 and Table 6 below were logged 
into the instrument to form part of the protocol to be used during each plate acquisition; 
furthermore the concentration of S1 in Table 2 appendix D were also logged into the protocol 
to facilitate the generation of the cytokine standard curve with concentrations of varying 
magnitude. The lot numbers of antibody bead concentrate, biotinylated antibody, and 
cytokine standards were logged into the assay protocol and saved; the logging of assay 
reagents lot numbers was verified during each assay. Kits of a single batch number were 
purchased to minimise inter-assay variation.  
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Table 5.Instrument setup details for detection and quantitation of cytokines 
Luminex ® instrument protocol setup details 
1 Appropriate Bead Region assigned according to Table 3.5 below. 
2 Count 100 events/bead regions. 
3 Set Minimum Events to 0. 
4 Set Sample Size to 75 μL. 
5 Set Flow Rate to 60 μL/ minute. 
6 Double Discriminator (DD) gate setting of 7,800-20,000. 
7.a Final plasma dilution 2 X at sample acquisition 
7.b Final NPA dilution 2.14 X at sample acquisition 
8 Enter S1 concentration (according to Table 3.2)  
9 Standard dilution 3 X 
 
Table 6.Cytokines and corresponding bead regions used during instrument setup. 
Cytokines and corresponding bead regions 
Cytokine  IL-8 IL-1β IL-4 IL-10 IL-13 IL-6 TNF-α  RANTES IL-9 IL-12 (p70) 
Bead 
Region 
78 13 77 15 18 19 52 21 44 42 
Cytokine MIP-1α IFN-γ IL-1α MCP-1 IL-5      
Bead 
Region 
26 38 37 29 34      
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Appendix G: Calculating Limit of detection for cytokines in plasma and 
nasopharyngeal aspirate 
An average standard curve equation estimated by the Bio-Plex software manager was 
selected and used to calculate the limit of detection (LOD) of each cytokine. The LOD was 
determined for cytokines in both the plasma and nasopharyngeal aspirates. The LOD for each 
of the 15 cytokines was determined as the concentration at the “average background MFI 
+2SD”. For each cytokine in the plasma or nasopharyngeal aspirate, the “average background 
MFI” was calculated as the average of MFI of all the blank samples. The LOD concentration 
was obtained by solving the 5 parameter logistic regression equation for “X” following 
substitution of “average background MFI +2SD” into the same equation as shown below in 
Table 8.  
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Table 8.LOD (pg/ml) calculations for plasma and nasopharyngeal aspirate assays 
 
Bio-Plex Estimated equation: FI=d+  (a-d)/〖[1+(X/C)^b]〗^g  
 
FI+2SD x = LOD 
Plasma cytokines     
IFN-γ FI = 2.03368 + (23363.0 - 2.03368) / ((1 + (x / 1874.89)^-1.00197))^1.01634 12.856 0.998 
IL-1α FI = 5.45600 + (169838 - 5.456) / ((1 + (x / 5.07881)^-0.188936))^10 283.792 8.918 
IL1-β 
FI = -6.72648 + (7971.38 + 6.72648) / ((1 + (x / 1503.09)^-
1.33452))^0.659796 259.255 31.723 
IL-4 
FI = -1.20993 + (12416.2 + 1.20993) / ((1 + (x / 4563.27)^-
2.06149))^0.436223 16.798 3.182 
IL-5 FI = 5.22173 + (25892.9 - 5.22173) / ((1 + (x / 944.779)^-1.48111))^0.692957 9.905 0.213 
IL-6 FI = 3.88705 + (14411.9 - 3.88705) / ((1 + (x / 676.063)^-1.57927))^0.608209 20.634 0.595 
IL-8 FI = 8.37847 + (13624.2 - 8.37847) / ((1 + (x / 1314.55)^-1.73642))^0.523127 64.103 3.09 
IL-9 FI = 15.5693 + (20424.7 - 15.5693) / ((1 + (x / 296.792)^-1.06792))^0.929186 159.457 2.023 
IL-10 FI = -7.00664 + (22161.2 + 7.00664) / ((1 + (x / 2224.86)^-2.19310))^0.38537 13.021 0.557 
IL12p70 FI = 1.87292 + (10441.8 - 1.87292) / ((1 + (x / 2253.02)^-1.20309))^1.00452 16.884 10.033 
IL-13 
FI = -1.42387 + (8444.02 + 1.42387) / ((1 + (x / 541.585)^-
1.43615))^0.779843 11.105 1.614 
MCP-1 FI = 3.91277 + (12511.0 - 3.91277) / ((1 + (x / 5712.15)^-2.72118))^0.392096 53.14 31.826 
MIP-1α FI = 1.70973 + (7506.49 - 1.70973) / ((1 + (x / 685.627)^-1.29031))^1.00738 18.473 6.272 
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RANTES 
FI = -17.3548 + (9790.39 + 17.3548) / ((1 + (x / 406.862)^-
10.5747))^0.0999999 108.112 6.596 
TNF-α FI = 6.46345 + (16615.7 - 6.46345) / ((1 + (x / 1160.09)^-1.76227))^0.57047 12.725 0.456 
Nasopharyngeal aspirate cytokines     
IFN-γ FI = 4.04801 + (1.77129E+007 - 4.04801) / ((1 + (x / 2519.85)^-0.152825))^10 12.534 1.051 
IL-1α FI = 177.297 + (74361.6 - 177.297) / ((1 + (x / 108.618)^-0.287646))^4.94589 437.678 7.769 
IL-1β FI = 108.415 + (9270.49 - 108.415) / ((1 + (x / 1433.07)^-1.42917))^0.716802 207.829 17.343 
IL-4 FI = 6.25544 + (14678.4 - 6.25544) / ((1 + (x / 2743.37)^-1.11492))^1.04461 14.735 4.553 
IL-5 FI = 3.45616 + (38529.8 - 3.45616) / ((1 + (x / 658.428)^-0.768026))^1.65900 8.732 0.615 
IL-6 FI = 1.35022 + (17586.5 - 1.35022) / ((1 + (x / 559.403)^-1.06364))^1.01951 14.417 0.729 
IL-8 FI = 41.3175 + (18682.2 - 41.3175) / ((1 + (x / 1114.66)^-0.901495))^1.20898 66.835 2.641 
IL-9 FI = 94.4956 + (23623.7 - 94.4956) / ((1 + (x / 308.194)^-0.968606))^1.10066 159.952 1.241 
IL-10 
FI = -1.59637 + (26787.6 + 1.59637) / ((1 + (x / 1789.14)^-
1.13173))^0.873295 11.903 0.824 
IL12p70 FI = 3.12984 + (14251.3 - 3.12984) / ((1 + (x / 1902.3)^-0.922135))^1.60872 14.484 15.708 
IL-13 FI = 1.05806 + (13009.9 - 1.05806) / ((1 + (x / 186.693)^-0.633489))^2.65011 10.913 2.88 
MCP-1 FI = 16.2316 + (12795.1 - 16.2316) / ((1 + (x / 5331.18)^-1.87259))^0.688083 35.952 35.057 
MIP-1α FI = 8.53779 + (8389.62 - 8.53779) / ((1 + (x / 379.757)^-0.940666))^1.76453 18.49 6.719 
RANTES FI = 23.8345 + (10475.8 - 23.8345) / ((1 + (x / 225.173)^-1.47845))^1.03919 57.079 5.347 
TNF-α FI = 1.47873 + (21487.1 - 1.47873) / ((1 + (x / 1270.06)^-1.14732))^0.928141 11.585 0.953 
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Appendix H: Cytokine standard curves produced during plasma and NPA assays 
The standard curves generated during the plasma and NPA assays are shown in the diagrams 
below. During plate 7 NPA assay the S1 was mistakenly not serially diluted; as a 
consequence the full reading of the S1-S9 curve were available and only S1 concentration 
and FI reading were available. The obtained S1 concentration and FI from plate 7 NPA assay 
for each and every cytokine were used to find the best representative curve among the 6 NPA 
assays that were already conducted. The NPA plate 7 standard curves for each cytokine were 
substituted with a standard curve from another NPA assay plate which had similar S1 
concentration and FI. The NPA assay/plate number that was used to substitute and interpolate 
the concentrations of plate 7 NPA assay are shown in the Figure of the respective cytokine 
standard curve. The substituted NPA plate 7 assays are shown in a dotted black line. 
   
Figure 5.1.Plasma assays IL-1β standard curves  
 
Figure 5.2.NPA assays IL-1β standard curves.  
126 
 
  
Figure 6.1.Plasma assays IL-10 standard curves. 
 
Figure 6.2.NPA assays IL-10 standard curves.  
  
Figure 7.1.Plasma assays IL-13 standard curves  
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Figure 7.2.NPA assays IL-13 standard curves.  
  
Figure 8.1.Plasma assays IL-6 standard curves.  
 
Figure 8.2.NPA assays IL-6 standard curves.  
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Figure 9.1.Plasma assays RANTES standard curves.  
 
Figure 9.2.NPA assays RANTES standard curves.  
 
 Figure 10.1.Plasma assays MIP-1α standard curves.  
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Figure 10.2.NPA assays MIP-1α standard curves.  
  
Figure 11.1.Plasma assays MCP-1 standard curves.  
 
Figure 11.2.NPA assays MCP-1 standard curves.  
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Figure 12.1.Plasma assays IL-5 standard curves.  
 
Figure 12.2.NPA assays IL-5 standard curves.  
  
Figure 13.1.Plasma assays IL-1α standard curves.  
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Figure 13.2.NPA assays IL-1α standard curves.  
 
Figure 14.1.Plasma assays IFN-γ standard curves.  
 
Figure 14.2.NPA assays IFN-γ standard curves.  
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Figure 15.1.Plasma assays IL-12p70 standard curves.  
 
Figure 15.2.NPA assays IL-12p70 standard curves.  
 
Figure 16.1.Plasma assays IL-9 standard curves.  
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Figure 16.2.NPA assays IL-9 standard curves.  
 
Figure 17.1.Plasma assays TNF-α standard curves.  
 
Figure 17.2.NPA assays TNF-α standard curves.  
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Figure 18.1.Plasma assays IL-4 standard curves.  
 
Figure 18.2.NPA assays IL-4 standard curves.  
 
Figure 19.1.Plasma assays IL-8 standard curves.  
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Figure 19.2.NPA assays IL-8 standard curves.  
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Appendix I: Levey Jennings Charts for Inter assay variability 
In all the Levey Jennings charts below; the blue squares show the observed fluorescence 
intensity, and the orange squares show observed concentration for the particular cytokine 
within the control sample that was included on each assay plate. All control samples were 
stored as single use aliquot and each aliquot was freshly thawed and included on each assay 
plate. Inter-assays that are not within the limits are discussed in the results and discussion 
section. Plate 1 control plasma sample had reduced concentration in all the cytokines of 
interest because it was not spiked. After analysis of plate 1 results, it was decided to create 
high concentration control and previously frozen plasma samples were quickly retrieved and 
spiked without being thawed (procedure performed on dry-ice). According to Westgard 
(1981), the assay results can be accepted provided that the control observations were affected 
by a justifiable event such as changing the control sample. 
Levey Jennings Charts: Inter assay variability for 15 cytokines during plasma assays 
 
Figure 20.1.Observed concentrations: inter assay variability for IL-1β during 7 plasma assays.  
 
Figure 20.2.Observed concentrations: inter assay variability for IL-1β during 7 plasma assays. 
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Figure 20.3.Observed concentrations: inter assay variability for IL-13 during 7 plasma assays. 
 
Figure 20.4.Observed concentrations: inter assay variability for IL-6 during 7 plasma assays. 
 
Figure 20.5.Observed concentrations: inter assay variability for RANTES during 7 plasma assays. 
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Figure 20.6.Observed concentrations: inter assay variability for MIP-1α during 7 plasma assays. 
 
Figure 20.7.Observed concentrations: inter assay variability for MCP-1 during 7 plasma assays. 
 
Figure 20.8.Observed concentrations: inter assay variability for IL-5 during 7 plasma assays. 
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Figure 20.9.Observed concentrations: inter assay variability for IL-1α during 7 plasma assays. 
 
Figure 20.10.Observed concentrations: inter assay variability for IFN-γ during 7 plasma assays. 
 
Figure 20.11.Observed concentrations: inter assay variability for IL-12p70 during 7 plasma assays. 
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Figure 20.12.Observed concentrations: inter assay variability for IL-9 during 7 plasma assays. 
 
Figure 20.13.Observed concentrations: inter assay variability for TNF-α during 7 plasma assays. 
 
Figure 20.14.Observed concentrations: inter assay variability for IL-4 during 7 plasma assays. 
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Figure 20.15.Observed concentrations: inter assay variability for IL-8 during 7 plasma assays. 
Levey Jennings Charts: Inter assay variability for 15 cytokines during NPA assays 
 
Figure 21.1.Observed concentrations: inter assay variability for IL-1β during 7 NPA assays. 
 
Figure 21.2.Observed concentrations: inter assay variability for IL-10 during 7 NPA assays. 
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Figure 21.3.Observed concentrations: inter assay variability for IL-13 during 7 NPA assays. 
 
Figure 21.4.Observed concentrations: inter assay variability for IL-6 during 7 NPA assays. 
 
Figure 21.5.Observed concentrations: inter assay variability for RANTES during 7 NPA assays.  
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Figure 21.6.Observed concentrations: inter assay variability for MIP-1α during 7 NPA assays. 
 
Figure 21.7.Observed concentrations: inter assay variability for MCP-1 during 7 NPA assays. 
 
Figure 21.8.Observed concentrations: inter assay variability for IL-5 during 7 NPA assays. 
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Figure 21.9.Observed concentrations: inter assay variability for IL-1α during 7 NPA assays 
 
Figure 21.10.Observed concentrations: inter assay variability for IFN-γ during 7 NPA assays 
 
Figure 21.11.Observed concentrations: inter assay variability for IL-12p70 during 7 NPA assays. 
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Figure 21.12.Observed concentrations: inter assay variability for IL-9 during 7 NPA assays 
 
Figure 21.13.Observed concentrations: inter assay variability for TNF-α during 7 NPA assays 
 
Figure 21.14.Observed concentrations: inter assay variability for IL-4 during 7 NPA assays 
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Figure 21.15.Observed concentrations: inter assay variability for IL-8 during 7 NPA assays 
